<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Bipolar disorder in adults: Choosing maintenance treatment</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Bipolar disorder in adults: Choosing maintenance treatment</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Bipolar disorder in adults: Choosing maintenance treatment</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert M Post, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Keck, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David Solomon, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 19, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Following remission of a bipolar mood episode, nearly all patients require maintenance treatment to delay or prevent another episode. Standard maintenance treatment consists of pharmacotherapy plus adjunctive psychotherapy. However, if psychotherapy is not available or is declined, pharmacotherapy alone is reasonable.</p><p>Selecting maintenance treatment for bipolar disorder is reviewed here. The use of adjunctive psychotherapy for maintenance treatment of bipolar disorder; management of poor adherence to maintenance pharmacotherapy; pharmacotherapy for acute bipolar mood episodes; teratogenic risks and neonatal issues involved in pharmacotherapy; and the epidemiology, clinical manifestations, and diagnosis of bipolar disorder are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/14666.html" rel="external">"Bipolar disorder in adults: Psychoeducation and other adjunctive maintenance psychotherapies"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/96007.html" rel="external">"Bipolar disorder in adults: Managing poor adherence to maintenance pharmacotherapy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/679.html" rel="external">"Bipolar mania and hypomania in adults: Choosing pharmacotherapy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15267.html" rel="external">"Bipolar major depression in adults: Choosing treatment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/17159.html" rel="external">"Teratogenicity, pregnancy complications, and postnatal risks of antipsychotics, benzodiazepines, lithium, and electroconvulsive therapy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/678.html" rel="external">"Bipolar disorder in adults: Epidemiology and pathogenesis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/14642.html" rel="external">"Bipolar disorder in adults: Clinical features"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/86602.html" rel="external">"Bipolar disorder in adults: Assessment and diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H123423"><span class="h1">DEFINITION OF BIPOLAR DISORDER</span><span class="headingEndMark"> — </span>Bipolar disorder is a mood disorder that is characterized by episodes of mania  (<a class="graphic graphic_table graphicRef91106" href="/d/graphic/91106.html" rel="external">table 1</a>), hypomania  (<a class="graphic graphic_table graphicRef91107" href="/d/graphic/91107.html" rel="external">table 2</a>), and major depression  (<a class="graphic graphic_table graphicRef91398" href="/d/graphic/91398.html" rel="external">table 3</a>) [<a href="#rid1">1</a>]. The subtypes of bipolar disorder include bipolar I and bipolar II. Patients with bipolar I disorder experience manic episodes, and nearly always experience hypomanic and major depressive episodes. Bipolar II disorder is marked by at least one hypomanic episode, at least one major depressive episode, and the absence of manic episodes. Additional information about the clinical features and diagnosis of bipolar disorder is discussed separately. (See  <a class="medical medical_review" href="/d/html/14642.html" rel="external">"Bipolar disorder in adults: Clinical features"</a> and  <a class="medical medical_review" href="/d/html/86602.html" rel="external">"Bipolar disorder in adults: Assessment and diagnosis", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H123830"><span class="h2">Recurrent mood episodes</span><span class="headingEndMark"> — </span>Bipolar disorder is characterized by recurrent mood episodes that can be life-threatening. As an example, the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) prospectively followed 858 patients who recovered from a mood episode, and found that within two years a recurrent episode occurred in nearly 50 percent, despite receiving treatment at specialty mood disorder clinics [<a href="#rid2">2</a>]. In addition, a meta-analysis of three studies lasting four years prospectively followed patients (n = 198) who recovered from an episode of mania and found that a recurrent mood episode occurred in 60 percent [<a href="#rid3">3</a>]. For each patient, manic and depressive episodes may recur in roughly equal proportions, or there may be a predominant polarity [<a href="#rid4">4</a>].</p><p>Recurrence of bipolar mood episodes is associated with a greater number of suicide attempts [<a href="#rid5">5-9</a>], as well as poorer social and occupational functioning [<a href="#rid10">10</a>] and cognitive impairment [<a href="#rid11">11</a>]. In addition, treatment resistance for each episode appears to increase with each additional recurrence [<a href="#rid12">12,13</a>].</p><p class="headingAnchor" id="H2"><span class="h1">INDICATIONS</span><span class="headingEndMark"> — </span>We suggest maintenance pharmacotherapy for nearly every euthymic patient with bipolar disorder, and observational studies support starting maintenance pharmacotherapy early in the course of illness [<a href="#rid14">14</a>]. As an example, a registry study found that starting <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> prophylaxis after a first manic or mixed episode was more effective than starting it later, such that hospitalization occurred less often (hazard ratio 0.75, 95% CI 0.67-0.84) [<a href="#rid14">14</a>]. Other observational studies suggest that maintenance treatment is indicated after a first manic episode based upon findings that cognitive dysfunction and brain volume deficits recover only if no further episodes occur over the course of the following year [<a href="#rid15">15,16</a>]. Adjunctive psychotherapy during maintenance treatment is also indicated for all bipolar patients to prevent relapses and enhance adherence. The goals for maintenance therapy are to reduce residual symptoms, delay and prevent recurrence of new mood episodes, reduce the risk of suicide, and improve psychosocial functioning. Maintenance pharmacotherapy for bipolar disorder is consistent with multiple practice guidelines [<a href="#rid17">17-20</a>].</p><p>Although most maintenance pharmacotherapy studies have primarily or exclusively enrolled patients with bipolar I disorder, we suggest maintenance treatment for bipolar II disorder as well. Patients with bipolar II disorder are symptomatically ill more than 50 percent of their lives following onset of the illness and are at high risk for suicide [<a href="#rid21">21</a>].</p><p>We also suggest maintenance pharmacotherapy for other specified bipolar disorder, based upon our clinical experience. Although there are no controlled trials or observational studies to guide management [<a href="#rid17">17,18</a>], the disorder is nevertheless a clinically significant syndrome that requires acute and maintenance treatment [<a href="#rid22">22,23</a>].</p><p>Suicide attempts may be minimized by maintenance therapy. An observational study of 406 patients followed for up to 22 years found that fewer suicide deaths occurred in bipolar patients who received maintenance treatment than those not treated (standardized mortality ratio 6 versus 27) [<a href="#rid24">24</a>]. Among medications used for bipolar disorder, <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> consistently has the best record for suicide prevention. (See  <a class="medical medical_review" href="/d/html/1708.html" rel="external">"Suicidal ideation and behavior in adults", section on 'Pharmacotherapy'</a>.)</p><p>In addition to preventing relapse in patients with bipolar disorder, maintenance pharmacotherapy may be associated with reduced rates of violent behavior. A national registry study identified 494 convictions for violent crime (eg, assault, robbery, or threats/intimidation) in 11,918 patients with bipolar disorder and examined the time periods when patients were or were not prescribed mood stabilizers (eg, <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a>, <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a>, <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a>, or <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>) or antipsychotics [<a href="#rid25">25</a>]. The rate of violent behavior when mood stabilizers were prescribed was 60 percent less, compared with times when mood stabilizers were not prescribed (hazard ratio 0.4, 95% CI 0.3-0.7). In addition, prescription of antipsychotics was associated with a 50 percent decrease in interpersonal violence (hazard ratio 0.5, 95% CI 0.3-0.9). Additional information about violent behavior in bipolar disorder is discussed separately. (See  <a class="medical medical_review" href="/d/html/14642.html" rel="external">"Bipolar disorder in adults: Clinical features", section on 'Perpetration'</a>.)</p><p class="headingAnchor" id="H9631558"><span class="h1">SELECTING A TREATMENT REGIMEN</span><span class="headingEndMark"> — </span>Pharmacotherapy is essential for maintenance treatment of bipolar disorder. The same medication regimen that was successfully used acutely is typically selected for maintenance treatment. However, some medications are preferable for maintenance treatment due to their demonstrated efficacy and tolerability. (See <a class="local">'Choosing pharmacotherapy'</a> below.)</p><p>In addition, we suggest combining pharmacotherapy with psychotherapy for maintenance treatment of bipolar disorder. Multiple randomized trials indicate that adjunctive group psychoeducation reduces the rate of recurrent mood episodes and enhances medication adherence. Add-on cognitive-behavioral therapy and family therapy can also improve adherence. (See <a class="local">'Choosing adjunctive psychotherapy'</a> below.)</p><p>However, it is reasonable to prescribe pharmacotherapy alone for maintenance treatment of bipolar disorder. Psychotherapy may not be available and some patients decline it.</p><p class="headingAnchor" id="H124117"><span class="h1">CHOOSING PHARMACOTHERAPY</span></p><p class="headingAnchor" id="H9625303"><span class="h2">First-line</span><span class="headingEndMark"> — </span>Maintenance pharmacotherapy usually consists of the same regimen that successfully treated the acute bipolar mood episode [<a href="#rid17">17,19,26</a>]. Studies that support this approach include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>In a randomized trial of 148 acutely manic patients who initially remitted with open-label divalproex (<a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a>) and were then assigned to maintenance treatment with divalproex, <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> (an efficacious maintenance treatment), or placebo, time to recurrence was significantly longer with divalproex compared with lithium or placebo [<a href="#rid27">27</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a randomized trial in which 1172 patients with a manic or depressive episode were initially stabilized with open-label <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a> and then assigned to maintenance quetiapine, <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a>, or placebo, time to recurrence was significantly longer with quetiapine compared to lithium or placebo [<a href="#rid28">28</a>].</p><p></p><p>Nevertheless, medications can be distinguished as first, second, and third-line maintenance treatments, based upon the quality and quantity of data that demonstrate the efficacy of each drug in preventing recurrent bipolar mood episodes. Medications also vary in the type, frequency, and severity of adverse effects, which influences clinician and patient preferences. As an example, a meta-analysis of six observational studies (n = 637 patients) found that the metabolic syndrome was present in more patients taking antipsychotics, compared with patients not treated with antipsychotics (45 versus 32 percent) [<a href="#rid29">29</a>].</p><p>Clinicians should initially attempt to manage patients with monotherapy to enhance compliance and minimize side effects and costs [<a href="#rid4">4</a>]. However, many patients require medication combinations for acute and maintenance treatment [<a href="#rid13">13</a>]. (See <a class="local">'Patients with frequent relapses or partial response'</a> below and  <a class="medical medical_review" href="/d/html/679.html" rel="external">"Bipolar mania and hypomania in adults: Choosing pharmacotherapy", section on 'Severe manic episodes'</a>.)</p><p class="headingAnchor" id="H9627866"><span class="h2">Second-line</span><span class="headingEndMark"> — </span>For patients who do not tolerate first-line maintenance pharmacotherapy (ie, the regimen that resolved the acute bipolar mood episode), the following medications are considered second-line monotherapy because each has consistently demonstrated its efficacy in multiple randomized trials; the drugs are presented in our general order of preference based upon efficacy in reducing the risk of suicide, the number of trials conducted, risk of side effects, and cost:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">Lithium</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">Valproate</a> (divalproex)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">Quetiapine</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">Lamotrigine</a></p><p></p><p>Use of <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a>, <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a>, <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a>, or <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a> as maintenance treatment is consistent with multiple practice guidelines [<a href="#rid18">18-20,30-33</a>].</p><p>Although we generally use <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a> as a second-line medication for maintenance treatment of bipolar disorder, we regard valproate as a third-line drug for female patients of childbearing potential. Many pregnancies are unplanned, and the drug is teratogenic and associated with cognitive impairment in the offspring [<a href="#rid34">34,35</a>]. In addition, female patients with bipolar disorder who are treated with valproate are at increased risk of polycystic ovary syndrome [<a href="#rid36">36</a>].</p><p class="headingAnchor" id="H9627960"><span class="h3">Lithium</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">Lithium</a> has been more widely studied than any other maintenance treatment for bipolar disorder. Using lithium reduces the risk of relapse by approximately 30 percent. Evidence for the efficacy of lithium includes the following:</p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis of five randomized trials (753 patients) that evaluated <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> for one to two years found relapses occurred in fewer patients who received lithium compared with placebo (risk ratio 0.7, 95% CI 0.5-0.9) [<a href="#rid37">37</a>]. Lithium appeared especially effective in preventing manic recurrences. However, discontinuation of treatment due to adverse events was three times greater with lithium than placebo (risk ratio 3, 95% CI 1-8).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A subsequent two-year randomized trial (n = 768) found that time to recurrence of mania or depression were each significantly longer in patients treated with <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> than placebo [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a randomized trial of patients with first-episode mania (n = 61), who were initially stabilized with <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> plus <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a> and then randomized to lithium or quetiapine for one year, overall psychopathology, depression, psychosis, and functioning were superior with lithium [<a href="#rid38">38</a>].</p><p></p><p>The administration and side effects of <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> are discussed separately. (See  <a class="medical medical_review" href="/d/html/15317.html" rel="external">"Bipolar disorder in adults and lithium: Pharmacology, administration, and management of adverse effects"</a>.)</p><p class="headingAnchor" id="H9628069"><span class="h4">Reduced risk of suicide</span><span class="headingEndMark"> — </span>High-quality studies that included patients with unipolar depressive disorders and patients with bipolar disorder have found that maintenance treatment with <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> reduces the risk of suicide. (See  <a class="medical medical_review" href="/d/html/1708.html" rel="external">"Suicidal ideation and behavior in adults", section on 'Pharmacotherapy'</a>.)</p><p>In addition, a meta-analysis of 31 observational studies and randomized trials compared maintenance treatment with <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> to treatment without lithium in patients with unipolar major depression, bipolar disorder, or schizoaffective disorder (n &gt;33,000) [<a href="#rid39">39</a>]. In the subgroup of bipolar patients (14 studies), suicide attempts and completed suicides occurred less often in patients who received lithium than patients who did not (relative risk 0.2, 95% CI 0.1-0.3). This was consistent with the finding in the total sample that suicide attempts and deaths occurred in fewer patients who received maintenance lithium.</p><p>A subsequent study of self-harm used electronic health records from a nationally representative sample to identify patients with bipolar disorder (n &gt;6000) who received maintenance monotherapy with <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a>, <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a>, <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a>, or <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a> [<a href="#rid40">40</a>]. Self-harm included any nonfatal act of self-injury, regardless of suicidal intent. Propensity scoring was used to match the patients with regard to observed potential confounders (eg, sex, comorbid disorders, and prior history of self-harm). The analyses found that time to self-harm was longer with lithium, compared with valproate (hazard ratio 1.31, 95% CI 1.01-1.70), olanzapine (hazard ratio 1.33, 95% CI 1.01-1.75), and quetiapine (hazard ratio 1.36, 95% CI 1.00-1.87). The rate of self-harm was comparable for valproate, olanzapine, or quetiapine.</p><p class="headingAnchor" id="H9628075"><span class="h3">Valproate</span><span class="headingEndMark"> — </span>Using <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a> reduces the risk of relapse by approximately 30 percent. Evidence for the efficacy of valproate as maintenance treatment includes a meta-analysis of six randomized trials (n = 876 euthymic bipolar patients) that evaluated valproate for 6 to 24 months; the primary findings were as follows [<a href="#rid41">41</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In two trials (n = 312) that compared <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a> with placebo, fewer recurrent mood episodes occurred in patients who received valproate (relative risk 0.7, 95% CI 0.5-0.9). Valproate appeared especially effective in preventing depressive recurrences. However, weight gain, tremor, and alopecia were more common with valproate than placebo, and discontinuation of treatment due to adverse effects was greater with valproate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Four trials (n = 618) compared <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a> with <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> and found that recurrence was comparable (relative risk 1.02, 95% CI 0.87-1.20). However, discontinuation of treatment due to intolerance or nonadherence occurred less often with valproate (relative risk 0.7, 95% CI 0.5-0.9).</p><p></p><p>The administration and side effects  (<a class="graphic graphic_table graphicRef59755" href="/d/graphic/59755.html" rel="external">table 4</a> and <a class="graphic graphic_table graphicRef78896" href="/d/graphic/78896.html" rel="external">table 5</a>) of <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a> are discussed separately. (See  <a class="medical medical_review" href="/d/html/679.html" rel="external">"Bipolar mania and hypomania in adults: Choosing pharmacotherapy", section on 'Valproate or divalproex'</a> and  <a class="medical medical_review" href="/d/html/2221.html" rel="external">"Antiseizure medications: Mechanism of action, pharmacology, and adverse effects", section on 'Valproate'</a>.)</p><p class="headingAnchor" id="H98758031"><span class="h3">Quetiapine</span><span class="headingEndMark"> — </span>Based upon multiple randomized trials, <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a> is a second-line maintenance treatment for bipolar disorder:</p><p class="bulletIndent1"><span class="glyph">●</span>A two-year trial randomly assigned patients (n = 1172) who were initially stabilized with open label <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a> to quetiapine (mean dose 546 mg per day), <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> (target trough serum concentration 0.6 to 1.2 mEq/L [0.6 to 1.2 mmol/L]), or placebo [<a href="#rid28">28</a>]. Time to recurrence of mania or depression was each longer in patients who received quetiapine than placebo. In addition, time to recurrence of depression was longer with quetiapine than lithium.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A one-year randomized trial that compared <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a> (300 or 600 mg per day) with placebo in 584 patients found that relapse occurred in fewer patients treated with quetiapine than placebo (24 versus 40 percent) [<a href="#rid42">42</a>]. Quetiapine appeared especially effective in preventing depressive recurrences. Discontinuation of treatment due to adverse events in patients treated with quetiapine 300 mg per day, quetiapine 600 mg per day, or placebo occurred in 8, 6, and 7 percent of patients.</p><p></p><p>In addition, <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a> plus <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> or divalproex is beneficial as maintenance treatment for bipolar disorder. (See <a class="local">'Lithium or valproate plus a second-generation antipsychotic'</a> below.)</p><p>The administration and side effects  (<a class="graphic graphic_table graphicRef82533" href="/d/graphic/82533.html" rel="external">table 6</a>) of <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a> are discussed separately. (See  <a class="medical medical_review" href="/d/html/15267.html" rel="external">"Bipolar major depression in adults: Choosing treatment"</a> and  <a class="medical medical_review" href="/d/html/679.html" rel="external">"Bipolar mania and hypomania in adults: Choosing pharmacotherapy", section on 'Second-generation'</a>.)</p><p class="headingAnchor" id="H9628194"><span class="h3">Lamotrigine</span><span class="headingEndMark"> — </span>Maintenance treatment with <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a> modestly reduces the risk of relapse by approximately 16 percent, compared with placebo. In addition, the efficacy of lamotrigine appears to be comparable to that for <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a>; however, tolerability is better with lamotrigine than lithium.</p><p>Evidence for the efficacy of <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a> includes the following:</p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis of three trials (n = 588) compared <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a> with placebo and found that lamotrigine was superior (risk ratio 0.84, 95% CI 0.71-0.99) [<a href="#rid37">37</a>]. Lamotrigine appeared more effective in delaying or preventing depression than mania or mood episodes with mixed features.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a meta-analysis of two trials (n = 387) that compared <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a> with <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a>, efficacy was comparable [<a href="#rid37">37</a>]. However, discontinuation of treatment due to adverse events occurred less often with lamotrigine than lithium (risk ratio 0.5, 95% CI 0.3-0.8).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A subsequent five year, open label, randomized trial (n = 155) compared <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a> with <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> and found that efficacy was comparable, but that tolerability was better with lamotrigine [<a href="#rid43">43</a>].</p><p></p><p>The administration and side effects  (<a class="graphic graphic_table graphicRef59755" href="/d/graphic/59755.html" rel="external">table 4</a> and <a class="graphic graphic_table graphicRef78896" href="/d/graphic/78896.html" rel="external">table 5</a>) of <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a> are discussed separately. (See  <a class="medical medical_review" href="/d/html/15267.html" rel="external">"Bipolar major depression in adults: Choosing treatment"</a> and  <a class="medical medical_review" href="/d/html/2221.html" rel="external">"Antiseizure medications: Mechanism of action, pharmacology, and adverse effects", section on 'Lamotrigine'</a>.)</p><p class="headingAnchor" id="H9629298"><span class="h2">Third-line</span><span class="headingEndMark"> — </span>Third-line maintenance monotherapy for bipolar disorder includes:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8786" href="/d/drug information/8786.html" rel="external">Aripiprazole</a> (oral or long acting injectable formulations)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">Olanzapine</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9868" href="/d/drug information/9868.html" rel="external">Risperidone</a> (oral or long acting injectable formulations)</p><p></p><p>The evidence for preventing recurrent mood episodes is less extensive and consistent for <a class="drug drug_general" data-topicid="8786" href="/d/drug information/8786.html" rel="external">aripiprazole</a> and <a class="drug drug_general" data-topicid="9868" href="/d/drug information/9868.html" rel="external">risperidone</a>, compared with second-line drugs. The efficacy of <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a> in preventing recurrence appears to be comparable to that of second-line drugs, but the tolerability of olanzapine is poorer. Use of aripiprazole, olanzapine, or risperidone as maintenance treatment is consistent with multiple practice guidelines [<a href="#rid17">17,18,20,30</a>].</p><p class="headingAnchor" id="H9629370"><span class="h3">Aripiprazole</span><span class="headingEndMark"> — </span>One randomized trial found that oral <a class="drug drug_general" data-topicid="8786" href="/d/drug information/8786.html" rel="external">aripiprazole</a> (mean dose 24 mg/day) was efficacious as maintenance treatment for bipolar disorder. In the 100 week trial (n = 161 patients), there were fewer recurrences in patients treated with aripiprazole than placebo (42 versus 63 percent) [<a href="#rid44">44</a>]. Common aripiprazole side effects included tremor, akathisia, hypertension, dry mouth, weight gain, vaginitis, and flu syndrome.</p><p>Randomized trials that studied <a class="drug drug_general" data-topicid="8786" href="/d/drug information/8786.html" rel="external">aripiprazole</a> as adjunctive maintenance treatment have yielded inconsistent results. (See <a class="local">'Patients with frequent relapses or partial response'</a> below.)</p><p>The administration and side effects  (<a class="graphic graphic_table graphicRef82533" href="/d/graphic/82533.html" rel="external">table 6</a>) of oral <a class="drug drug_general" data-topicid="8786" href="/d/drug information/8786.html" rel="external">aripiprazole</a> are discussed separately. (See  <a class="medical medical_review" href="/d/html/679.html" rel="external">"Bipolar mania and hypomania in adults: Choosing pharmacotherapy", section on 'Second-generation'</a>.)</p><p class="headingAnchor" id="H3415725700"><span class="h4">Long-acting injectable aripiprazole</span><span class="headingEndMark"> — </span>Patients with bipolar disorder who are stabilized on daily oral <a class="drug drug_general" data-topicid="8786" href="/d/drug information/8786.html" rel="external">aripiprazole</a> may prefer a regimen of long-acting injectable (depot) aripiprazole once every four weeks for maintenance pharmacotherapy. However, many patients refuse depot aripiprazole because they dislike receiving injections, and most clinicians and experts do not use depot medications [<a href="#rid45">45</a>]. In addition, long-acting injectable antipsychotics do not necessarily improve adherence. (See  <a class="medical medical_review" href="/d/html/96007.html" rel="external">"Bipolar disorder in adults: Managing poor adherence to maintenance pharmacotherapy", section on 'Long-acting injectable antipsychotics'</a>.)</p><p>Evidence regarding the efficacy of long-acting injectable <a class="drug drug_general" data-topicid="8786" href="/d/drug information/8786.html" rel="external">aripiprazole</a> as maintenance treatment for bipolar disorder includes a 52-week randomized trial that compared long-acting injectable aripiprazole with injectable placebo in 266 patients [<a href="#rid46">46</a>]. Patients were enrolled during an episode of mania, stabilized on oral aripiprazole (15 to 30 mg/day), then stabilized on long-acting injectable aripiprazole (either 300 mg or 400 mg every month), and then randomly assigned to injectable aripiprazole or injectable placebo. Relapse of mood episodes occurred in fewer patients treated with active drug than placebo (27 versus 51 percent). Specifically, active drug was effective for preventing mania but not depression. During the stabilization phase prior to randomization, adverse events due to aripiprazole included akathisia (17 percent), weight increase (11 percent), insomnia (10 percent), and anxiety (7 percent). During the randomized phase, these four side effects occurred more often with long-acting injectable aripiprazole than placebo; nevertheless, it appeared that discontinuation of treatment due to side effects occurred less often with aripiprazole than placebo (17 versus 26 percent of patients).</p><p class="headingAnchor" id="H9629382"><span class="h3">Olanzapine</span><span class="headingEndMark"> — </span>Although multiple studies have consistently found that <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a> delays or prevents recurrences of bipolar disorder [<a href="#rid47">47,48</a>], we use olanzapine as a third-line maintenance treatment because it causes serious weight gain and may also cause diabetes mellitus [<a href="#rid49">49-51</a>].</p><p>Five randomized trials with different designs have studied <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a> for maintenance treatment of bipolar disorder [<a href="#rid47">47,48</a>]. As an example, a 48-week trial compared olanzapine (mean dose 13 mg per day) with placebo in 361 patients and found that relapse occurred in fewer patients who received olanzapine than placebo (47 versus 80 percent) [<a href="#rid52">52</a>]. Olanzapine appeared to delay or prevent mania more effectively than major depression [<a href="#rid47">47,48</a>].</p><p>The administration and side effects  (<a class="graphic graphic_table graphicRef82533" href="/d/graphic/82533.html" rel="external">table 6</a>) of <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a> are discussed separately. (See  <a class="medical medical_review" href="/d/html/679.html" rel="external">"Bipolar mania and hypomania in adults: Choosing pharmacotherapy", section on 'Second-generation'</a>.)</p><p class="headingAnchor" id="H187415045"><span class="h3">Risperidone</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9868" href="/d/drug information/9868.html" rel="external">Risperidone</a> may help prevent recurrence of bipolar mood episodes; when we prescribe the drug, we typically use the daily oral formulation. Although long-acting injections every two weeks are a reasonable alternative, many patients refuse depot risperidone because they dislike receiving injections, and most clinicians and experts do not use depot risperidone [<a href="#rid45">45</a>]. In addition, long-acting injectable antipsychotics do not necessarily improve adherence. (See  <a class="medical medical_review" href="/d/html/96007.html" rel="external">"Bipolar disorder in adults: Managing poor adherence to maintenance pharmacotherapy", section on 'Long-acting injectable antipsychotics'</a>.)</p><p>No randomized trials have evaluated oral <a class="drug drug_general" data-topicid="9868" href="/d/drug information/9868.html" rel="external">risperidone</a> for maintenance treatment of bipolar disorder; however, randomized trials have found that long-acting injectable (depot) risperidone may be efficacious. Also, randomized trials with other second-generation antipsychotics, such as <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a> and <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a>, provide indirect evidence that supports using oral risperidone.</p><p>Two randomized trials have evaluated long-acting injectable (depot) <a class="drug drug_general" data-topicid="9868" href="/d/drug information/9868.html" rel="external">risperidone</a> as maintenance treatment for patients whose acute mania was initially stabilized with open label risperidone. Only one trial was positive:</p><p class="bulletIndent1"><span class="glyph">●</span>One two-year trial (n = 303) compared depot <a class="drug drug_general" data-topicid="9868" href="/d/drug information/9868.html" rel="external">risperidone</a> (generally 25 mg every two weeks) with placebo; recurrent mood episodes occurred in fewer patients who received risperidone than placebo (29 versus 52 percent) [<a href="#rid53">53</a>]. Risperidone appeared more efficacious in delaying or preventing mania than major depression.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An 18-month trial (n = 398) compared depot <a class="drug drug_general" data-topicid="9868" href="/d/drug information/9868.html" rel="external">risperidone</a> (generally 25 mg every two weeks) plus oral placebo, injectable placebo plus oral placebo, and injectable placebo plus oral <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a> (10 mg per day) [<a href="#rid54">54</a>]. Recurrence was comparable for depot risperidone plus oral placebo, compared with placebo injection plus oral placebo (39 and 56 percent of patients). By contrast, recurrent mood episodes occurred in fewer patients treated with placebo injection plus oral olanzapine, compared with placebo injection plus oral placebo (24 versus 56 percent).</p><p></p><p>A third trial found that long-acting injectable <a class="drug drug_general" data-topicid="9868" href="/d/drug information/9868.html" rel="external">risperidone</a> plus <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> or divalproex was beneficial as maintenance treatment for bipolar disorder. (See <a class="local">'Lithium or valproate plus a second-generation antipsychotic'</a> below.)</p><p>The administration  (<a class="graphic graphic_table graphicRef59201" href="/d/graphic/59201.html" rel="external">table 7</a>) and side effects  (<a class="graphic graphic_table graphicRef82533" href="/d/graphic/82533.html" rel="external">table 6</a>) of long-acting injectable <a class="drug drug_general" data-topicid="9868" href="/d/drug information/9868.html" rel="external">risperidone</a> are discussed separately in the context of schizophrenia. (See  <a class="medical medical_review" href="/d/html/15250.html" rel="external">"Schizophrenia in adults: Pharmacotherapy with long-acting injectable antipsychotic medication"</a>.)</p><p class="headingAnchor" id="H9630397"><span class="h2">Other options</span><span class="headingEndMark"> — </span>For the many bipolar patients who are refractory to maintenance treatment with first, second, or third-line medications, other options include <a class="drug drug_general" data-topicid="8630" href="/d/drug information/8630.html" rel="external">asenapine</a>, <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="16085" href="/d/drug information/16085.html" rel="external">lurasidone</a>, <a class="drug drug_general" data-topicid="9467" href="/d/drug information/9467.html" rel="external">oxcarbazepine</a>, or <a class="drug drug_general" data-topicid="10174" href="/d/drug information/10174.html" rel="external">paliperidone</a>. However, the evidence supporting the use of these other options is less compelling compared with second and third-line drugs, as well as certain medication combinations. (See <a class="local">'Second-line'</a> above and <a class="local">'Third-line'</a> above and <a class="local">'Patients with frequent relapses or partial response'</a> below.)</p><p class="headingAnchor" id="H9630403"><span class="h3">Asenapine</span><span class="headingEndMark"> — </span>A 49-week, double-blind, extension study was conducted with 218 patients who completed a three-week randomized trial that compared <a class="drug drug_general" data-topicid="8630" href="/d/drug information/8630.html" rel="external">asenapine</a> with <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a> for treatment of acute manic or mixed episodes; the efficacy of asenapine and olanzapine as maintenance treatment appeared to be comparable [<a href="#rid55">55</a>]. In a subsequent study, patients with manic or mixed episodes who responded to asenapine (n = 253) were randomly assigned to maintain asenapine for 26 weeks or switch to placebo; time to recurrence of any mood episode was longer with asenapine [<a href="#rid56">56</a>].</p><p>The administration and side effects  (<a class="graphic graphic_table graphicRef82533" href="/d/graphic/82533.html" rel="external">table 6</a>) of <a class="drug drug_general" data-topicid="8630" href="/d/drug information/8630.html" rel="external">asenapine</a> are discussed separately. (See  <a class="medical medical_review" href="/d/html/679.html" rel="external">"Bipolar mania and hypomania in adults: Choosing pharmacotherapy", section on 'Second-generation'</a>.)</p><p class="headingAnchor" id="H9630409"><span class="h3">Carbamazepine</span><span class="headingEndMark"> — </span>A meta-analysis of four randomized maintenance trials (n = 464) compared <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a> with <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> and found that prevention of recurrence or hospitalization was comparable; however, none of the studies included a placebo arm [<a href="#rid57">57</a>]. Many clinicians attempt to achieve a target 12-hour serum trough carbamazepine concentration of 4 to 8 mcg/mL, but there is no relationship between this blood level range and efficacy for maintenance treatment of bipolar disorder. The administration and side effects  (<a class="graphic graphic_table graphicRef59755" href="/d/graphic/59755.html" rel="external">table 4</a> and <a class="graphic graphic_table graphicRef78896" href="/d/graphic/78896.html" rel="external">table 5</a>) of carbamazepine are discussed separately. (See  <a class="medical medical_review" href="/d/html/679.html" rel="external">"Bipolar mania and hypomania in adults: Choosing pharmacotherapy", section on 'Carbamazepine'</a> and  <a class="medical medical_review" href="/d/html/2221.html" rel="external">"Antiseizure medications: Mechanism of action, pharmacology, and adverse effects", section on 'Carbamazepine'</a>.)</p><p class="headingAnchor" id="H818998427"><span class="h3">Lurasidone</span><span class="headingEndMark"> — </span>A maintenance trial involved 496 patients with acute bipolar mood episodes who were initially stabilized on <a class="drug drug_general" data-topicid="16085" href="/d/drug information/16085.html" rel="external">lurasidone</a> (20 to 80 mg/day) in combination with either <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> or <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a>, and then randomized to lurasidone or placebo (plus lithium or valproate) for 28 weeks [<a href="#rid58">58</a>]. Across multiple outcome measures, time to recurrence of mood episodes was generally comparable in the two groups.</p><p>The administration and side effects  (<a class="graphic graphic_table graphicRef82533" href="/d/graphic/82533.html" rel="external">table 6</a>) of <a class="drug drug_general" data-topicid="16085" href="/d/drug information/16085.html" rel="external">lurasidone</a> are discussed separately. (See  <a class="medical medical_review" href="/d/html/16693.html" rel="external">"Bipolar major depression in adults: Efficacy and adverse effects of second-generation antipsychotics", section on 'Lurasidone'</a>.)</p><p class="headingAnchor" id="H9630415"><span class="h3">Oxcarbazepine</span><span class="headingEndMark"> — </span>A systematic review found insufficient evidence to recommend <a class="drug drug_general" data-topicid="9467" href="/d/drug information/9467.html" rel="external">oxcarbazepine</a> for maintenance treatment of bipolar disorder [<a href="#rid59">59</a>]. However, oxcarbazepine is an alternative to <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>, based upon limited evidence of effectiveness in treating acute mood episodes and its structural similarity to carbamazepine [<a href="#rid60">60-62</a>]. In addition, oxcarbazepine is generally better tolerated and is easier to prescribe because it does not induce its own metabolism, as carbamazepine does. The administration and side effects  (<a class="graphic graphic_table graphicRef59755" href="/d/graphic/59755.html" rel="external">table 4</a> and <a class="graphic graphic_table graphicRef78896" href="/d/graphic/78896.html" rel="external">table 5</a>) of oxcarbazepine are discussed separately. (See  <a class="medical medical_review" href="/d/html/2221.html" rel="external">"Antiseizure medications: Mechanism of action, pharmacology, and adverse effects", section on 'Oxcarbazepine'</a>.)</p><p class="headingAnchor" id="H9630421"><span class="h3">Paliperidone</span><span class="headingEndMark"> — </span>A two year randomized maintenance trial compared <a class="drug drug_general" data-topicid="10174" href="/d/drug information/10174.html" rel="external">paliperidone</a> extended release (median dose 6 mg per day) with placebo in 290 patients with bipolar disorder who initially remitted from acute manic or mixed episodes with paliperidone [<a href="#rid63">63</a>]. The median time to recurrence was longer in patients who received paliperidone than placebo (558 versus 283 days). The study also included 82 patients who remitted with <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a> and were maintained on it (median dose 10 mg per day). In this non-randomized arm, time to recurrence was longer with olanzapine than in either the randomized paliperidone or placebo arms.</p><p>The administration and side effects  (<a class="graphic graphic_table graphicRef82533" href="/d/graphic/82533.html" rel="external">table 6</a>) of <a class="drug drug_general" data-topicid="10174" href="/d/drug information/10174.html" rel="external">paliperidone</a> are discussed separately.</p><p class="headingAnchor" id="H9625289"><span class="h2">Patients with frequent relapses or partial response</span><span class="headingEndMark"> — </span>Relapse frequently occurs in bipolar disorder despite maintenance monotherapy. The evidence supports using medication combinations (polypharmacy) for acute and maintenance treatment of these relapses [<a href="#rid64">64</a>]. Medication combinations are also used for patients who have a partial but inadequate response to a maintenance drug that is tolerated. </p><p>Most patients with a past history of multiple (eg, three) recurrences are treated acutely for subsequent mood episodes with a medication combination [<a href="#rid65">65-67</a>]; the combination should be continued for maintenance treatment because the increased efficacy of medication combinations often outweighs the increased side effects and costs [<a href="#rid68">68</a>]. In addition, for patients who have a partial but inadequate response to monotherapy that is tolerated, we suggest adding a second medication. Among the many possible medications combinations, we suggest <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> or divalproex plus a second-generation antipsychotic, which several trials have found is more efficacious than either lithium or divalproex monotherapy [<a href="#rid69">69-73</a>]. Lithium plus <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a>, <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>, or <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a> are reasonable alternatives.</p><p>The majority of randomized trials that have tested medication combinations have initially treated the acute mood episode with the combination. Following remission, patients were randomly assigned to maintenance treatment with the combination or monotherapy (by substituting placebo for one of the medications in the combination).</p><p>Clinicians prescribing medication combinations for maintenance therapy should try to follow certain principles [<a href="#rid64">64,74</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Attempt to prescribe only two medications, although three may be necessary</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The combination should not pose significantly greater safety or tolerability risks than monotherapy; however, tolerability can be worse with combined treatments than monotherapy, especially if each drug is not carefully titrated to below its side effects threshold</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The combined drugs should not have the same or opposing mechanisms of action</p><p></p><p>In addition, clinicians need to be aware of possible pharmacokinetic interactions. As an example, divalproex (<a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a>) inhibits hepatic P450 enzymes and metabolism of concomitant medications. Conversely, <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a> induces hepatic enzymes and metabolism of concomitant medications. Specific drug-drug interactions can be determined using the <a class="external" href="/drug-interactions">drug interactions program</a> included in UpToDate.</p><p class="headingAnchor" id="H9626383"><span class="h3">Lithium or valproate plus a second-generation antipsychotic</span><span class="headingEndMark"> — </span>Randomized maintenance trials for bipolar disorder have found that <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> or divalproex plus a second-generation antipsychotic is superior to lithium or <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a> monotherapy [<a href="#rid69">69-73</a>]. In order of preference, we suggest adjunctive <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a>, long-acting injectable <a class="drug drug_general" data-topicid="9868" href="/d/drug information/9868.html" rel="external">risperidone</a> (oral risperidone is a reasonable alternative), <a class="drug drug_general" data-topicid="10040" href="/d/drug information/10040.html" rel="external">ziprasidone</a>, <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a>, or <a class="drug drug_general" data-topicid="8786" href="/d/drug information/8786.html" rel="external">aripiprazole</a>:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Quetiapine</strong> – Two similar randomized trials that each lasted two years compared adjunctive <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a> with placebo in patients receiving <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> or divalproex (total n = 1334) [<a href="#rid69">69,70</a>]. Relapse occurred in fewer patients treated with adjunctive quetiapine compared with placebo (19 and 20 versus 49 and 52 percent). Consistent with this finding, a pooled subgroup analysis of 445 patients who initially remitted from mood episodes with mixed features prior to maintenance treatment found that there were fewer recurrences with adjunctive quetiapine than placebo (21 versus 54 percent) [<a href="#rid75">75</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Long-acting injectable </strong><strong>risperidone</strong><strong> </strong>– In a one-year randomized trial (124 patients treated with <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a>, divalproex, and/or other medications), recurrence occurred in fewer patients who received adjunctive long-acting injectable <a class="drug drug_general" data-topicid="9868" href="/d/drug information/9868.html" rel="external">risperidone</a> compared with placebo (23 versus 46 percent) [<a href="#rid71">71</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ziprasidone</strong> – In a six-month randomized trial (240 patients treated with <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> or divalproex), the median time to a mood episode was longer in patients who received adjunctive <a class="drug drug_general" data-topicid="10040" href="/d/drug information/10040.html" rel="external">ziprasidone</a> compared with placebo (43 versus 27 days) [<a href="#rid73">73</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Olanzapine</strong> – In an 18-month randomized trial (68 asymptomatic patients treated with <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> or <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a>), the median time to relapse of symptoms was longer for adjunctive <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a> compared with placebo (163 versus 42 days) [<a href="#rid72">72</a>]. However, time to relapse of a mood syndrome (mania or depression) was comparable for the two groups, as was the number of patients with syndromic relapse.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Aripiprazole</strong> – One maintenance trial of adjunctive <a class="drug drug_general" data-topicid="8786" href="/d/drug information/8786.html" rel="external">aripiprazole</a> found that the drug was efficacious, whereas a smaller and shorter trial did not:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A one-year randomized trial compared adjunctive <a class="drug drug_general" data-topicid="8786" href="/d/drug information/8786.html" rel="external">aripiprazole</a> with placebo in 337 patients treated with <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> or <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a> [<a href="#rid76">76</a>]. Recurrence occurred in fewer patients who received add-on aripiprazole than placebo (17 versus 29 percent).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A six-month randomized trial compared <a class="drug drug_general" data-topicid="8786" href="/d/drug information/8786.html" rel="external">aripiprazole</a> plus divalproex with placebo plus divalproex in 83 patients, and found that there was a trend for a longer time to relapse in patients treated with adjunctive aripiprazole [<a href="#rid77">77</a>].</p><p></p><p>Additional information about <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a>, divalproex, <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a>, long-acting injectable <a class="drug drug_general" data-topicid="9868" href="/d/drug information/9868.html" rel="external">risperidone</a>, <a class="drug drug_general" data-topicid="10040" href="/d/drug information/10040.html" rel="external">ziprasidone</a>, <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a>, and <a class="drug drug_general" data-topicid="8786" href="/d/drug information/8786.html" rel="external">aripiprazole</a> is discussed separately. (See <a class="local">'Lithium'</a> above and <a class="local">'Valproate'</a> above and <a class="local">'Quetiapine'</a> above and <a class="local">'Risperidone'</a> above and <a class="local">'Olanzapine'</a> above and  <a class="medical medical_review" href="/d/html/14776.html" rel="external">"Second-generation antipsychotic medications: Pharmacology, administration, and side effects"</a>.)</p><p>Open-label prospective or retrospective studies suggest that <a class="drug drug_general" data-topicid="9289" href="/d/drug information/9289.html" rel="external">clozapine</a> added to any combination of <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a>, anticonvulsants, antidepressants, or anxiolytics may delay or prevent relapse of bipolar mood episodes [<a href="#rid78">78-80</a>]. Clozapine can cause a potentially lethal agranulocytosis, and thus requires regular monitoring of white blood cell counts every one or two weeks. In addition, clozapine should not be combined with <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a> because they both adversely affect hematopoiesis. Additional information about the administration and side effects  (<a class="graphic graphic_table graphicRef82533" href="/d/graphic/82533.html" rel="external">table 6</a>) of clozapine is discussed separately.</p><p>For patients who respond to maintenance treatment with an adjunctive second-generation antipsychotic, we suggest continuing the antipsychotic for a minimum of six months. Although maintaining the drug for longer (eg, two years) is reasonable, if adverse effects such as weight gain intervene after six months, it is appropriate to then taper and discontinue the antipsychotic over two to four weeks. Evidence supporting this approach includes the randomized trials described immediately above. In addition, a study enrolled patients (n = 159) who were successfully treated for mania with <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> (0.6 to 1.2 mmol/L) or <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a> (350 to 830 micromol/L) plus <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a> (5 to 25 mg/day) or <a class="drug drug_general" data-topicid="9868" href="/d/drug information/9868.html" rel="external">risperidone</a> (1 to 6 mg/day) [<a href="#rid81">81</a>]. After two to six weeks of remission, patients were randomly assigned to placebo substitution for the antipsychotic at randomization (monotherapy), placebo substitution for the antipsychotic at 6 months, or combination treatment for the entire 12 months of the study. Relapse occurred more often in the monotherapy group than the 6- and 12-month groups, but was comparable for the 6- and 12-month groups. The estimated rate of relapse at one year in the monotherapy, six-month, and 12-month groups was 85 versus 65 and 65 percent.</p><p>Additional information about duration of maintenance treatment is discussed elsewhere in this topic. (See <a class="local">'Maintenance of medications'</a> below.)</p><p class="headingAnchor" id="H9626404"><span class="h3">Lithium plus an anticonvulsant</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">Lithium</a> combined with an anticonvulsant is often more effective than lithium monotherapy for maintenance treatment of bipolar disorder [<a href="#rid82">82-84</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In a two-year, open label randomized trial (n = 220 patients), relapse occurred in fewer patients treated with <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> plus <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a> than valproate monotherapy (54 versus 69 percent) [<a href="#rid85">85</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a one-year randomized trial (n = 52 patients), <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> plus <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a> led to fewer mood episodes per year compared with lithium alone or carbamazepine alone (4.6 versus 6.3 and 6.7) [<a href="#rid86">86</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A randomized trial compared <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a> plus <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> with placebo plus lithium in 124 patients and found that the median time to relapse with adjunctive lamotrigine and placebo was 10 and 4 months [<a href="#rid87">87</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A one-year randomized trial (n = 55) compared <a class="drug drug_general" data-topicid="9467" href="/d/drug information/9467.html" rel="external">oxcarbazepine</a> plus <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> with placebo plus lithium and found that recurrence with adjunctive oxcarbazepine and with placebo was 38 and 59 percent [<a href="#rid88">88</a>]. Although the difference was not statistically significant, a difference of this magnitude, if real, would be clinically meaningful.</p><p></p><p class="headingAnchor" id="H346572103"><span class="h3">Other combinations</span><span class="headingEndMark"> — </span>A one-year randomized trial (n = 351 patients) that compared <a class="drug drug_general" data-topicid="8786" href="/d/drug information/8786.html" rel="external">aripiprazole</a> plus <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a> with placebo plus lamotrigine found that the estimated rate of relapse was comparable (11 and 23 percent of patients) [<a href="#rid89">89</a>].</p><p class="headingAnchor" id="H170721354"><span class="h2">Potentially problematic drugs</span></p><p class="headingAnchor" id="H11464920"><span class="h3">Antidepressants</span><span class="headingEndMark"> — </span>There are some concerns that maintenance treatment with antidepressants may destabilize patients with bipolar disorder. The use of antidepressants for maintenance treatment of bipolar disorder is discussed separately. (See  <a class="medical medical_review" href="/d/html/14655.html" rel="external">"Bipolar major depression in adults: Efficacy and adverse effects of antidepressants"</a>.)</p><p class="headingAnchor" id="H170721370"><span class="h3">Benzodiazepines</span><span class="headingEndMark"> — </span>Benzodiazepines during maintenance treatment may be associated with an increased risk of recurrence. An observational study from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) examined 1365 patients who recovered from a mood episode [<a href="#rid90">90</a>]. After adjusting for potential confounds, use of a benzodiazepine on a standing or as-needed basis following recovery was associated with an increased risk of recurrence (hazard ratio 1.21, 95% CI 1.01-1.45). Comparable effects were observed in additional analyses from the same study, including one that stratified the sample by propensity score (a summary measure of the likelihood of receiving a benzodiazepine). However, patients with a greater likelihood of suffering relapses may have been more likely to receive benzodiazepines.</p><p class="headingAnchor" id="H93483"><span class="h1">MONITORING</span><span class="headingEndMark"> — </span>We suggest regularly monitoring patients with self-report rating scales during ongoing treatment (often referred to as measurement based care). Although there is no evidence demonstrating that this practice improves outcomes, possible benefits include identifying nonresponders, detecting residual or prodromal symptoms, and helping patients recognize the degree of improvement or lack thereof. In addition, patients may become more engaged in treatment as they take an active role, and may be able to relate specific behaviors with symptomatic changes.</p><p>Measurement based care can be implemented with self-report measures that are in the public domain (free), require little additional time on the part of the clinician, and approximately 5 to 10 minutes for patients to complete while waiting for their appointments [<a href="#rid91">91</a>]. Reasonable options in order of preference include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>The Life Chart Method  (<a class="graphic graphic_figure graphicRef96534" href="/d/graphic/96534.html" rel="external">figure 1</a>), with which patients rate their overall mood on a daily basis; the rating is completed at the end of each day. A prospective study found preliminary evidence of good validity for patient self-reports [<a href="#rid92">92</a>]. Prior studies have established the reliability and validity of clinician ratings using the instrument [<a href="#rid93">93,94</a>]. In addition, a <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.healthyinfo.com%2Fconsumers%2Fho%2Fbipolar%2FMood.Diaries%2FNIMH.Mood.Diary.Pt.Instructions.pdf&amp;token=mATAnM5AfSrFaboXskHmf6cu0jRQsKsjItB3EwVSrSE3NCyIUD5gPgkaudWMEmksn7LuxHGcKTcpj%2FjGKVL3kjlbVu%2BvvxCZOWH51gyLZ%2FEB9ki7M0HWGgcbzK236YN1&amp;TOPIC_ID=680" target="_blank">manual</a> that provides standardized instructions for patients is available.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The first 13 items of the Mood Disorder Questionnaire  (<a class="graphic graphic_table graphicRef53409" href="/d/graphic/53409.html" rel="external">table 8</a>) to track symptoms of mania/hypomania (validity has been established for clinician ratings but not for patient self-reports) [<a href="#rid95">95</a>], as well as the nine-item Patient Health Questionnaire  (<a class="graphic graphic_table graphicRef59307" href="/d/graphic/59307.html" rel="external">table 9</a>) to track symptoms of depression (this instrument is well established for patients with unipolar depression) [<a href="#rid96">96</a>]. Patients can complete these instruments in approximately 5 to 10 minutes while waiting for their appointments [<a href="#rid91">91</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A single Likert response item  (<a class="graphic graphic_form graphicRef84011" href="/d/graphic/84011.html" rel="external">form 1</a>) that assesses mood on a daily basis, and is anchored on one end with 0 for very sad, 10 on the other end for very happy, and 5 in the middle for normal mood (euthymia).</p><p></p><p>Other alternatives include the <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fdepts.washington.edu%2Fpsychres%2Fwordpress%2Fwp-content%2Fuploads%2F2017%2F09%2Finternalstates_scale.pdf&amp;token=6f0zSSJOAPvMAHE6WC9JR%2BCgiQpFrzWnjqUFjbQt8ib0Ea1jhbBpKNP8Pnb%2BwdHRR%2F%2FHOS6K6xtGtOvYQe%2F7i6om98d4TXVi1LCB2NrBHIVf5Hg3GAOwNHduTWB6ORuk&amp;TOPIC_ID=680" target="_blank">Internal State Scale</a> [<a href="#rid97">97</a>] as well as instruments that can be downloaded from the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.dbsalliance.org%2F&amp;token=ZAuWdG5s4GIvjFnkWRP6rC6dBWU8%2FMZEcwGeeAm5c58EpMgcvhu2s4%2FQc68YQejm&amp;TOPIC_ID=680" target="_blank">Depression and Bipolar Support Alliance</a> website. In addition, My Mood Monitor is a 27-item instrument that is used to screen for multiple psychiatric disorders including bipolar disorder; the instrument can be downloaded from the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.annfammed.org%2Fcontent%2Fsuppl%2F2010%2F03%2F04%2F8.2.160.DC1&amp;token=OkRvQff7BG2kfcurzcRiOuqqkqrVeRf01ZPR4p%2FzbJQQSnS0p77pnOMWlv9GkDSnZoiuCjbGUZmxZJJciiNyrnMExl%2B8%2BLoosg%2B87Go9rGk%3D&amp;TOPIC_ID=680" target="_blank">journal website</a> for longitudinal monitoring [<a href="#rid98">98</a>].</p><p>Additional information about measurement based care, including the Patient Health Questionnaire, is discussed separately in the context of depression. (See  <a class="medical medical_review" href="/d/html/14860.html" rel="external">"Using scales to monitor symptoms and treat depression (measurement based care)"</a>.)</p><p class="headingAnchor" id="H259506092"><span class="h1">MAINTENANCE OF MEDICATIONS</span></p><p class="headingAnchor" id="H933548338"><span class="h2">Duration</span><span class="headingEndMark"> — </span>The duration of maintenance treatment will vary for each patient. Most patients require maintenance treatment for many years, and some patients require it their entire lives because medications are not curative [<a href="#rid99">99</a>]. Maintenance treatment should last longer for patients with a more severe course of illness. Factors to consider include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Number of years the patient has had bipolar disorder</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lifetime number of mood episodes and hospitalizations, the length of time required to stabilize the patient after each episode, and how many years have elapsed since the last episode</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lifetime number of suicide attempts and their lethality</p><p></p><p class="headingAnchor" id="H15312584"><span class="h2">Discontinuation</span><span class="headingEndMark"> — </span>Most patients require maintenance treatment for many years, and some patients require it for their entire lives. However, patients may want to stop maintenance medications because of side effects, inadequate response, medical illness, pregnancy, or a wish to be medication-free after a prolonged period of euthymia.</p><p class="headingAnchor" id="H495538713"><span class="h3">Discontinuing lithium</span><span class="headingEndMark"> — </span>Discontinuing stable treatment usually leads to a new mood episode:</p><p class="bulletIndent1"><span class="glyph">●</span>In a review of 14 <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> maintenance treatment studies that involved discontinuation of lithium in 257 patients who had previously been stable for a mean of 30 months, more than 50 percent of the patients suffered a recurrence within 10 weeks of discontinuing lithium, and about 90 percent relapsed within the first year off of treatment [<a href="#rid100">100</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a subsequent study, among 32 patients successfully treated with maintenance <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> for a minimum of five years, 32 percent suffered a recurrence within one month of discontinuing lithium, and 62 percent within one year [<a href="#rid101">101</a>].</p><p></p><p>Other risks of stopping maintenance treatment include hospitalization, persistent subsyndromal symptoms, family and economic losses, and suicide. Psychoeducation may help discourage patients from discontinuing effective maintenance treatment. (See  <a class="medical medical_review" href="/d/html/96007.html" rel="external">"Bipolar disorder in adults: Managing poor adherence to maintenance pharmacotherapy", section on 'Consequences'</a> and  <a class="medical medical_review" href="/d/html/14666.html" rel="external">"Bipolar disorder in adults: Psychoeducation and other adjunctive maintenance psychotherapies", section on 'Group psychoeducation'</a>.)</p><p>If patients insist on stopping treatment, we suggest slowly tapering one medication at a time, over a period of several weeks to months. Clinicians should also monitor patients frequently for prodromal symptoms of early recurrence. Prospective, open-label studies show that tapering maintenance medication more slowly is associated with lower rates of recurrence, but that most patients suffer a recurrence despite the slower taper:</p><p class="bulletIndent1"><span class="glyph">●</span>In 78 patients who were effectively maintained on <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> for a mean of four years and then discontinued it, recurrence within two years was significantly greater in patients who stopped lithium in less than two weeks compared with discontinuation over two to four weeks (95 versus 69 percent) [<a href="#rid102">102</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In 64 patients who were stable on maintenance <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> for a mean of four years and then discontinued it, recurrence within five years was significantly greater in patients who stopped lithium in less than two weeks compared with discontinuation over two to four weeks (94 versus 53 percent) [<a href="#rid103">103</a>].</p><p></p><p class="headingAnchor" id="H1845737263"><span class="h3">Discontinuing antipsychotic</span><span class="headingEndMark"> — </span>Maintenance of antipsychotic treatment appears to lower the risk of recurrence of symptoms in individuals who are stabilized on medications. As an example, in a meta-analysis of eight studies and over 2900 subjects, individuals with bipolar I disorder (stabilized on mood stabilizer plus second-generation antipsychotic) were maintained on either mood stabilizer plus second-generation antipsychotic (n = 1456) versus mood stabilizer plus placebo (n = 1476) [<a href="#rid104">104</a>]. At six months, individuals in the treatment group (second-generation antipsychotic plus mood stabilizer) exhibited a lower recurrence than the control group (mood stabilizer plus placebo) of any mood episode (relative risk 0.51, 95% CI 0.39-0.86), manic/hypomanic or mixed episode (relative risk 0.42, 95% CI 0.3-0.59), and depressive episode (relative risk 0.39, 95% CI 0.28-0.54). Additionally, the secondary outcome (recurrence at 12 months) showed similar lower recurrence rates for the second-generation antipsychotic plus mood stabilizer group versus mood stabilizer plus placebo group for each type of recurrence.</p><p class="headingAnchor" id="H2819449375"><span class="h2">Patient considerations</span><span class="headingEndMark"> — </span>Some patients are discouraged by the prospect of taking medications "forever" [<a href="#rid4">4</a>]. Female patients may interrupt maintenance treatment in order to conceive children, others may have intolerable side effects that may truncate maintenance treatment. We educate patients about the course of illness in bipolar disorder and the potential benefits of ongoing treatment. Additionally, we emphasize that in the context of the long-term relationship with the patient the need for maintenance treatment will periodically be re-evaluated based on their progress in maintaining symptomatic and functional stability. It may also help to point out that other chronic illnesses such as hypertension, diabetes mellitus, and asthma often require lifetime medications. Additional information about adherence with maintenance medications for bipolar disorder is discussed separately. (See  <a class="medical medical_review" href="/d/html/96007.html" rel="external">"Bipolar disorder in adults: Managing poor adherence to maintenance pharmacotherapy"</a>.)</p><p>Based upon clinical experience, discontinuation of maintenance pharmacotherapy may be more successful for patients who have established relationships with their clinicians, as well as patients who have relatively few current psychosocial stressors such as relationship or occupational difficulties, getting married, or graduating from school. We typically educate patients about relapse prevention (eg, identifying prodromal symptoms and avoiding risk factors for relapse such as substance abuse), and assist in developing a plan for patients and families to follow should relapse occur.</p><p class="headingAnchor" id="H20"><span class="h1">CHOOSING ADJUNCTIVE PSYCHOTHERAPY</span><span class="headingEndMark"> — </span>Although pharmacotherapy is the cornerstone of maintenance treatment for bipolar disorder, adjunctive psychotherapy can help prevent relapses and improve medication adherence. As an example, a meta-analysis of eight randomized trials (n = 830 patients) compared psychotherapy (eg, group psychoeducation, cognitive-behavioral therapy, or family therapy) plus pharmacotherapy with pharmacotherapy alone; the probability of relapse was lower in patients treated with adjunctive psychotherapy (odds ratio 0.5, 95% CI 0.4-0.7) [<a href="#rid105">105</a>]. Adjunctive psychotherapy is typically administered during maintenance treatment to euthymic patients, who are typically better able to participate in psychotherapy than acutely ill patients [<a href="#rid106">106</a>].</p><p>However, if adjunctive psychotherapy is used during an acute mood episode, the same psychotherapy is usually retained for maintenance treatment. This practice is supported by a randomized trial of 82 patients with acute mood episodes who were stabilized for four weeks with pharmacotherapy plus one of two randomly assigned adjunctive psychotherapies (either interpersonal and social rhythm therapy or the control therapy, called intensive clinical management) [<a href="#rid107">107</a>]. Following stabilization, patients were randomly assigned again to maintenance treatment with the same psychotherapy or to switch to the other psychotherapy. Relapse occurred in fewer patients who maintained the same therapy compared with those who switched (18 versus 40 percent).</p><p>Choosing a specific adjunctive psychotherapy is based upon the quality and quantity of data that demonstrate its efficacy in preventing recurrent bipolar mood episodes, as well as its beneficial effects upon medication adherence.</p><p class="headingAnchor" id="H9632073"><span class="h2">First-line</span><span class="headingEndMark"> — </span>For bipolar patients receiving maintenance pharmacotherapy, we suggest adjunctive group psychoeducation as first-line psychotherapy. Psychoeducation is a structured, time-limited program that teaches patients and family members about bipolar disorder, including its pathogenesis, clinical features, course of illness, and treatment; the program also addresses detecting prodromal symptoms. Nearly all other types of psychotherapy used for bipolar disorder include an element of psychoeducation because of its demonstrated success and the ease of administration. Several randomized trials indicate that group psychoeducation is efficacious both for preventing recurrent mood episodes and improving adherence to pharmacotherapy. The efficacy, administration, and content of group psychoeducation are discussed separately. (See  <a class="medical medical_review" href="/d/html/14666.html" rel="external">"Bipolar disorder in adults: Psychoeducation and other adjunctive maintenance psychotherapies", section on 'Group psychoeducation'</a> and  <a class="medical medical_review" href="/d/html/96007.html" rel="external">"Bipolar disorder in adults: Managing poor adherence to maintenance pharmacotherapy", section on 'Group psychoeducation'</a>.)</p><p class="headingAnchor" id="H9631607"><span class="h2">Second-line</span><span class="headingEndMark"> — </span>Bipolar patients receiving maintenance pharmacotherapy may decline or not have access to group psychoeducation, or may continue to demonstrate poor adherence despite treatment with group psychoeducation. For these patients, we suggest either adjunctive cognitive-behavioral therapy (CBT) or family therapy for enhancing poor medication adherence. Multiple randomized trials indicate that CBT and family therapy are each efficacious for improving adherence. (See  <a class="medical medical_review" href="/d/html/96007.html" rel="external">"Bipolar disorder in adults: Managing poor adherence to maintenance pharmacotherapy", section on 'Specific interventions'</a>.)</p><p>The efficacy of CBT and of family therapy for delaying or preventing recurrent bipolar mood episodes is not clear, due to inconsistent results across different randomized trials. (See  <a class="medical medical_review" href="/d/html/14666.html" rel="external">"Bipolar disorder in adults: Psychoeducation and other adjunctive maintenance psychotherapies"</a>.)</p><p class="headingAnchor" id="H11465621"><span class="h1">ELECTROCONVULSIVE THERAPY</span><span class="headingEndMark"> — </span>Maintenance electroconvulsive therapy (ECT) has been used for patients who respond to ECT for treatment of acute mood episodes and subsequently fail many other maintenance medication regimens and psychotherapies [<a href="#rid18">18</a>]. Most of the evidence supporting the effectiveness and tolerability of maintenance ECT comes from small observational studies [<a href="#rid108">108-116</a>]. In one three-year retrospective study including 43 individuals with bipolar disorder, the number of psychiatric hospitalizations and the mean annual number of days hospitalized were lower during maintenance ECT compared with the time period before initiation of maintenance ECT (number of psychiatric hospitalizations: 8 versus 32; relative risk 0.24, 95% CI 0.13-0.43; number of days hospitalized: 115 versus 826; relative risk 0.14, 95% CI 0.07-0.29, respectively) [<a href="#rid117">117</a>]. Of the 37 individuals who were hospitalized before maintenance ECT, only 14 of them were hospitalized during the course of maintenance ECT (ie, 62 percent reduction in hospitalization). Furthermore, only individuals who were hospitalized prior to maintenance ECT were hospitalized during the maintenance treatment.</p><p>Maintenance medications, including anticonvulsants, are often prescribed in conjunction with maintenance ECT.</p><p>Additional information about using ECT for bipolar disorder, as well as an overview of ECT and the technique for performing ECT, are discussed separately. (See  <a class="medical medical_review" href="/d/html/14659.html" rel="external">"Bipolar disorder in adults: Indications for and efficacy of electroconvulsive therapy"</a> and  <a class="medical medical_review" href="/d/html/1709.html" rel="external">"Overview of electroconvulsive therapy (ECT) for adults"</a> and  <a class="medical medical_review" href="/d/html/1712.html" rel="external">"Technique for performing electroconvulsive therapy (ECT) in adults"</a>.)</p><p class="headingAnchor" id="H293414665"><span class="h1">SELF-MANAGEMENT</span><span class="headingEndMark"> — </span>Patients who can take responsibility for their health may perhaps benefit from self-management strategies that include measures to [<a href="#rid118">118</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Calm oneself and cope with stress (eg, scheduling relaxing activities or learning mindfulness-based stress reduction).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Optimize medical management by adhering to treatment and recognizing prodromal signs. Regular mood charting  (<a class="graphic graphic_figure graphicRef96534" href="/d/graphic/96534.html" rel="external">figure 1</a>) may be helpful. (See <a class="local">'Monitoring'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Maintain hope, for example, understanding that bipolar disorder is a medical disorder that can be treated and if current treatment is not working sufficiently, there are many other alternatives.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Engage in physical activity and exercise (eg, bicycle riding or walking).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Maintain a healthy diet.</p><p></p><p>However, some self-management interventions may not prevent relapses of mood episodes. As an example, a 16-week randomized trial compared usual care plus a smartphone application with usual care alone in 205 patients with bipolar I disorder who did not have a current mood episode [<a href="#rid119">119</a>]. The self-management intervention consisted of a smartphone application and nonclinician coaches, and included self-assessment of medication adherence and wellness, and prompts to contact clinicians when indicated. At the week 48 follow-up assessment, time to recurrence of bipolar mood episodes in the two groups was comparable.</p><p class="headingAnchor" id="H28812346"><span class="h1">GERIATRIC PATIENTS</span><span class="headingEndMark"> — </span>Maintenance treatment for geriatric bipolar disorder is discussed separately. (See  <a class="medical medical_review" href="/d/html/16645.html" rel="external">"Geriatric bipolar disorder: Maintenance treatment"</a>.)</p><p class="headingAnchor" id="H263769161"><span class="h1">FEMALE PATIENTS</span><span class="headingEndMark"> — </span>For female patients who are at high risk of unintended pregnancies (eg, become hypersexual when manic or have a history of irregular use of contraceptives), we try to avoid using teratogenic drugs, especially <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a>, but also <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a> and <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a>. The teratogenic and postnatal risks caused by these drugs are discussed separately. (See  <a class="medical medical_review" href="/d/html/17159.html" rel="external">"Teratogenicity, pregnancy complications, and postnatal risks of antipsychotics, benzodiazepines, lithium, and electroconvulsive therapy"</a> and  <a class="medical medical_review" href="/d/html/2218.html" rel="external">"Risks associated with epilepsy during pregnancy and the postpartum period", section on 'Effects of ASMs on the fetus and child'</a>.)</p><p class="headingAnchor" id="H4468938"><span class="h2">Pregnancy</span><span class="headingEndMark"> — </span>Preconception and prenatal maintenance pharmacotherapy for bipolar patients, and contraception and preconception counseling for bipolar disorder are discussed separately. (See  <a class="medical medical_review" href="/d/html/16971.html" rel="external">"Bipolar disorder in women: Preconception and prenatal maintenance pharmacotherapy"</a> and  <a class="medical medical_review" href="/d/html/82834.html" rel="external">"Bipolar disorder in women: Indications for preconception and prenatal maintenance pharmacotherapy"</a> and  <a class="medical medical_review" href="/d/html/15701.html" rel="external">"Bipolar disorder in women: Contraception and preconception assessment and counseling"</a>.)</p><p class="headingAnchor" id="H4109433704"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/115361.html" rel="external">"Society guideline links: Bipolar disorder"</a>.)</p><p class="headingAnchor" id="H26"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (See  <a class="medical medical_basics" href="/d/html/15348.html" rel="external">"Patient education: Bipolar disorder (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/16338.html" rel="external">"Patient education: Coping with high drug prices (The Basics)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (See  <a class="medical medical_patient" href="/d/html/4869.html" rel="external">"Patient education: Bipolar disorder (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/16279.html" rel="external">"Patient education: Coping with high prescription drug prices in the United States (Beyond the Basics)"</a>.)</p><p></p><p>These educational materials can be used as part of psychoeducational psychotherapy. (See <a class="local">'First-line'</a> above.)</p><p>The National Institute of Mental Health also has educational material explaining the symptoms, course of illness, and treatment of bipolar disorder in a booklet entitled "Bipolar Disorder," which is available online at the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nimh.nih.gov%2Fhealth%2Fpublications%2Fbipolar-disorder&amp;token=c9TXCEotcdMcarRyXBEnhwgIEx3THC4PwSF2z%2FRKFh%2B8HmGSkeqm5bDBx4bOcfNh0qAPwOVFAtZ6twY6hM0vtq8AtSQsFLDSFqHlsS1NKKs%3D&amp;TOPIC_ID=680" target="_blank">website</a> or through a toll-free number, 866-615-6464. The web site also provides references, summaries of study results in language intended for the lay public, and information about clinical trials currently recruiting patients.</p><p>More comprehensive information is provided in many books written for patients and family members, including The Bipolar Disorder Survival Guide: What You and Your Family Need to Know, written by David J. Miklowitz, PhD (published by The Guilford Press, 2002); An Unquiet Mind: A Memoir of Moods and Madness, written by Kay Jamison, PhD (published by Random House, 1995); and Treatment of Bipolar Illness: A Casebook for Clinicians and Patients, by RM Post, MD, and GS Leverich, LCSW (published by Norton Press, 2008).</p><p>The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.dbsalliance.org%2F&amp;token=ZAuWdG5s4GIvjFnkWRP6rC6dBWU8%2FMZEcwGeeAm5c58EpMgcvhu2s4%2FQc68YQejm&amp;TOPIC_ID=680" target="_blank">Depression and Bipolar Support Alliance</a> (800-826-3632) is a national organization that educates members about bipolar disorder and how to cope with it. Other functions include increasing public awareness of the illness and advocating for more research and services. The organization is administered and maintained by patients and family members, and has local chapters.</p><p>The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nami.org%2FHome&amp;token=wEsKVFvqlKzpT%2BqOtddW%2F8kABYN690CzsdrTBuRq2QekIBbQQeqX70Vmx%2B0z8d0m&amp;TOPIC_ID=680" target="_blank">National Alliance on Mental Illness</a> (800-950-6264) is a similarly structured organization devoted to education, support, and advocacy for patients with any mental illness. Bipolar disorder is one of their priorities.</p><p class="headingAnchor" id="H27"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications</strong> – Bipolar disorder is a highly recurrent illness. For euthymic patients with bipolar I disorder, we recommend maintenance pharmacotherapy rather than no treatment (<a class="grade" href="https://medilib.ir/uptodate/show/grade_1" rel="external">Grade 1A</a>). We also suggest maintenance treatment for patients with bipolar II disorder rather than no treatment (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Patients with other specified bipolar disorder are likely to benefit from maintenance treatment as well. (See <a class="local">'Indications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>First-line treatment</strong> – For most patients who respond to acute pharmacotherapy, we suggest maintenance treatment with the same regimen, rather than switching medications (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'First-line'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Second- and third-line treatment </strong>– For patients who do not tolerate the initial course of maintenance pharmacotherapy and were not treated with <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a>, we suggest lithium monotherapy over other medication regimens (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>).</p><p></p><p class="bulletIndent1">For patients who do not respond to or tolerate <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a>, we suggest <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a>, <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a>, or <a class="drug drug_general" data-topicid="9545" href="/d/drug information/9545.html" rel="external">lamotrigine</a> rather than other medications (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). For patients who do not respond to or cannot tolerate these drugs, <a class="drug drug_general" data-topicid="8786" href="/d/drug information/8786.html" rel="external">aripiprazole</a>, <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a>, or <a class="drug drug_general" data-topicid="9868" href="/d/drug information/9868.html" rel="external">risperidone</a> are reasonable alternatives. (See <a class="local">'Second-line'</a> above and <a class="local">'Third-line'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with frequent relapses or partial response</strong> – For patients who have a history of multiple recurrences or have a partial but inadequate response to a maintenance drug that is tolerated, we suggest adding a second medication (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). Common combinations include <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> or <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproate</a>, plus a second-generation antipsychotic, such as <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a>, long-acting injectable <a class="drug drug_general" data-topicid="9868" href="/d/drug information/9868.html" rel="external">risperidone</a>, <a class="drug drug_general" data-topicid="10040" href="/d/drug information/10040.html" rel="external">ziprasidone</a>, or <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a>. Other combinations that are useful include lithium plus valproate or <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>. (See <a class="local">'Patients with frequent relapses or partial response'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adjunctive psychotherapy</strong> – For patients with bipolar disorder, we suggest adjunctive psychoeducation for euthymic patients rather than no psychotherapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Group psychoeducation as adjunctive treatment with pharmacotherapy can prevent recurrent mood episodes and enhance medication adherence. Adjunctive cognitive-behavioral therapy or family therapy are each a reasonable alternative to psychoeducation for management of poor adherence to pharmacotherapy. (See <a class="local">'Choosing adjunctive psychotherapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring</strong> – Monitoring bipolar patients with rating scales during ongoing treatment may identify nonresponders, detect residual symptoms, and help patients recognize improvement. Clinicians can track symptoms of mania/hypomania with the first 13 items of the Mood Disorder Questionnaire  (<a class="graphic graphic_table graphicRef53409" href="/d/graphic/53409.html" rel="external">table 8</a>), and symptoms of depression with the nine-item Patient Health Questionnaire  (<a class="graphic graphic_table graphicRef59307" href="/d/graphic/59307.html" rel="external">table 9</a>). (See <a class="local">'Monitoring'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration of treatment</strong> – Most patients require maintenance treatment for many years, and some patients require it their entire lives. (See <a class="local">'Duration'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, Arlington, VA 2013.</li><li><a class="nounderline abstract_t">Perlis RH, Ostacher MJ, Patel JK, et al. Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry 2006; 163:217.</a></li><li><a class="nounderline abstract_t">Gignac A, McGirr A, Lam RW, Yatham LN. Recovery and recurrence following a first episode of mania: a systematic review and meta-analysis of prospectively characterized cohorts. J Clin Psychiatry 2015; 76:1241.</a></li><li><a class="nounderline abstract_t">Gitlin M, Frye MA. Maintenance therapies in bipolar disorders. Bipolar Disord 2012; 14 Suppl 2:51.</a></li><li><a class="nounderline abstract_t">Leverich GS, Altshuler LL, Frye MA, et al. Factors associated with suicide attempts in 648 patients with bipolar disorder in the Stanley Foundation Bipolar Network. J Clin Psychiatry 2003; 64:506.</a></li><li><a class="nounderline abstract_t">Oquendo MA, Mann JJ. Identifying and managing suicide risk in bipolar patients. J Clin Psychiatry 2001; 62 Suppl 25:31.</a></li><li><a class="nounderline abstract_t">Rucci P, Frank E, Kostelnik B, et al. Suicide attempts in patients with bipolar I disorder during acute and maintenance phases of intensive treatment with pharmacotherapy and adjunctive psychotherapy. Am J Psychiatry 2002; 159:1160.</a></li><li><a class="nounderline abstract_t">Slama F, Bellivier F, Henry C, et al. Bipolar patients with suicidal behavior: toward the identification of a clinical subgroup. J Clin Psychiatry 2004; 65:1035.</a></li><li><a class="nounderline abstract_t">Fagiolini A, Kupfer DJ, Rucci P, et al. Suicide attempts and ideation in patients with bipolar I disorder. J Clin Psychiatry 2004; 65:509.</a></li><li><a class="nounderline abstract_t">Nolen WA, Luckenbaugh DA, Altshuler LL, et al. Correlates of 1-year prospective outcome in bipolar disorder: results from the Stanley Foundation Bipolar Network. Am J Psychiatry 2004; 161:1447.</a></li><li><a class="nounderline abstract_t">Yurgelun-Todd D, Sneider J. Neurocognitive deficits in bipolar disorder. Clinical Approaches in Bipolar Disorder 2006; 5:51.</a></li><li><a class="nounderline abstract_t">Post RM. Mechanisms of illness progression in the recurrent affective disorders. Neurotox Res 2010; 18:256.</a></li><li><a class="nounderline abstract_t">Post RM, Altshuler LL, Frye MA, et al. Complexity of pharmacologic treatment required for sustained improvement in outpatients with bipolar disorder. J Clin Psychiatry 2010; 71:1176.</a></li><li><a class="nounderline abstract_t">Kessing LV, Vradi E, Andersen PK. Starting lithium prophylaxis early v. late in bipolar disorder. Br J Psychiatry 2014; 205:214.</a></li><li><a class="nounderline abstract_t">Kozicky JM, Torres IJ, Silveira LE, et al. Cognitive change in the year after a first manic episode: association between clinical outcome and cognitive performance early in the course of bipolar I disorder. J Clin Psychiatry 2014; 75:e587.</a></li><li><a class="nounderline abstract_t">Kozicky JM, McGirr A, Bond DJ, et al. Neuroprogression and episode recurrence in bipolar I disorder: A study of gray matter volume changes in first-episode mania and association with clinical outcome. Bipolar Disord 2016; 18:511.</a></li><li><a class="nounderline abstract_t">Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord 2013; 15:1.</a></li><li><a class="nounderline abstract_t">Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder. World J Biol Psychiatry 2013; 14:154.</a></li><li class="breakAll">United Kingdom National Institute for Health and Care Excellence (NICE). Bipolar disorder: The assessment and management of bipolar disorder in adults, children and young people in primary and secondary care. NICE Clinical Guideline 185, September 2014. http://www.nice.org.uk/guidance/cg185 (Accessed on September 01, 2015).</li><li><a class="nounderline abstract_t">Goodwin GM, Haddad PM, Ferrier IN, et al. Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2016; 30:495.</a></li><li><a class="nounderline abstract_t">Judd LL, Akiskal HS, Schettler PJ, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003; 60:261.</a></li><li><a class="nounderline abstract_t">Merikangas KR, Jin R, He JP, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry 2011; 68:241.</a></li><li><a class="nounderline abstract_t">Smith DJ, Griffiths E, Kelly M, et al. Unrecognised bipolar disorder in primary care patients with depression. Br J Psychiatry 2011; 199:49.</a></li><li><a class="nounderline abstract_t">Angst F, Stassen HH, Clayton PJ, Angst J. Mortality of patients with mood disorders: follow-up over 34-38 years. J Affect Disord 2002; 68:167.</a></li><li><a class="nounderline abstract_t">Fazel S, Zetterqvist J, Larsson H, et al. Antipsychotics, mood stabilisers, and risk of violent crime. Lancet 2014; 384:1206.</a></li><li><a class="nounderline abstract_t">Malhi GS, Adams D, Cahill CM, et al. The management of individuals with bipolar disorder: a review of the evidence and its integration into clinical practice. Drugs 2009; 69:2063.</a></li><li><a class="nounderline abstract_t">McElroy SL, Bowden CL, Collins MA, et al. Relationship of open acute mania treatment to blinded maintenance outcome in bipolar I disorder. J Affect Disord 2008; 107:127.</a></li><li><a class="nounderline abstract_t">Weisler RH, Nolen WA, Neijber A, et al. Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study). J Clin Psychiatry 2011; 72:1452.</a></li><li><a class="nounderline abstract_t">Vancampfort D, Vansteelandt K, Correll CU, et al. Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators. Am J Psychiatry 2013; 170:265.</a></li><li><a class="nounderline abstract_t">Ostacher MJ, Tandon R, Suppes T. Florida Best Practice Psychotherapeutic Medication Guidelines for Adults With Bipolar Disorder: A Novel, Practical, Patient-Centered Guide for Clinicians. J Clin Psychiatry 2016; 77:920.</a></li><li><a class="nounderline abstract_t">Malhi GS, Gessler D, Outhred T. The use of lithium for the treatment of bipolar disorder: Recommendations from clinical practice guidelines. J Affect Disord 2017; 217:266.</a></li><li><a class="nounderline abstract_t">Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord 2018; 20:97.</a></li><li><a class="nounderline abstract_t">Malhi GS, Bell E, Bassett D, et al. The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry 2021; 55:7.</a></li><li class="breakAll">National Institute for Health and Care Excellence (NICE). Antenatal and postnatal mental health: clinical management and service guidance. NICE clinical guideline 192. December 2014. http://www.nice.org.uk/guidance/cg192 (Accessed on May 16, 2016).</li><li class="breakAll">Briggs GG, Freeman RK. Valproic acid. In: Drugs in pregnancy and lactation: A reference guide to fetal and neonatal risk, Tenth Edition, Wolters Kluwer, Philadelphia 2015. p.1449.</li><li><a class="nounderline abstract_t">Zhang L, Li H, Li S, Zou X. Reproductive and metabolic abnormalities in women taking valproate for bipolar disorder: a meta-analysis. Eur J Obstet Gynecol Reprod Biol 2016; 202:26.</a></li><li><a class="nounderline abstract_t">Smith LA, Cornelius V, Warnock A, et al. Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: a systematic review of randomized controlled trials. Bipolar Disord 2007; 9:394.</a></li><li><a class="nounderline abstract_t">Berk M, Daglas R, Dandash O, et al. Quetiapine v. lithium in the maintenance phase following a first episode of mania: randomised controlled trial. Br J Psychiatry 2017; 210:413.</a></li><li><a class="nounderline abstract_t">Baldessarini RJ, Tondo L, Davis P, et al. Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. Bipolar Disord 2006; 8:625.</a></li><li><a class="nounderline abstract_t">Hayes JF, Pitman A, Marston L, et al. Self-harm, Unintentional Injury, and Suicide in Bipolar Disorder During Maintenance Mood Stabilizer Treatment: A UK Population-Based Electronic Health Records Study. JAMA Psychiatry 2016; 73:630.</a></li><li><a class="nounderline abstract_t">Cipriani A, Reid K, Young AH, et al. Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder. Cochrane Database Syst Rev 2013; :CD003196.</a></li><li><a class="nounderline abstract_t">Young AH, McElroy SL, Olausson B, et al. A randomised, placebo-controlled 52-week trial of continued quetiapine treatment in recently depressed patients with bipolar I and bipolar II disorder. World J Biol Psychiatry 2014; 15:96.</a></li><li><a class="nounderline abstract_t">Licht RW, Nielsen JN, Gram LF, et al. Lamotrigine versus lithium as maintenance treatment in bipolar I disorder: an open, randomized effectiveness study mimicking clinical practice. The 6th trial of the Danish University Antidepressant Group (DUAG-6). Bipolar Disord 2010; 12:483.</a></li><li><a class="nounderline abstract_t">Keck PE Jr, Calabrese JR, McIntyre RS, et al. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry 2007; 68:1480.</a></li><li><a class="nounderline abstract_t">Velligan DI, Weiden PJ, Sajatovic M, et al. Strategies for addressing adherence problems in patients with serious and persistent mental illness: recommendations from the expert consensus guidelines. J Psychiatr Pract 2010; 16:306.</a></li><li><a class="nounderline abstract_t">Calabrese JR, Sanchez R, Jin N, et al. Efficacy and Safety of Aripiprazole Once-Monthly in the Maintenance Treatment of Bipolar I Disorder: A Double-Blind, Placebo-Controlled, 52-Week Randomized Withdrawal Study. J Clin Psychiatry 2017; 78:324.</a></li><li><a class="nounderline abstract_t">Cipriani A, Rendell JM, Geddes J. Olanzapine in long-term treatment for bipolar disorder. Cochrane Database Syst Rev 2009; :CD004367.</a></li><li><a class="nounderline abstract_t">Cipriani A, Rendell J, Geddes JR. Olanzapine in the long-term treatment of bipolar disorder: a systematic review and meta-analysis. J Psychopharmacol 2010; 24:1729.</a></li><li><a class="nounderline abstract_t">Leslie DL, Rosenheck RA. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry 2004; 161:1709.</a></li><li><a class="nounderline abstract_t">Fernandez-Egea E, Miller B, Garcia-Rizo C, et al. Metabolic effects of olanzapine in patients with newly diagnosed psychosis. J Clin Psychopharmacol 2011; 31:154.</a></li><li><a class="nounderline abstract_t">Raedler TJ. Cardiovascular aspects of antipsychotics. Curr Opin Psychiatry 2010; 23:574.</a></li><li><a class="nounderline abstract_t">Tohen M, Calabrese JR, Sachs GS, et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry 2006; 163:247.</a></li><li><a class="nounderline abstract_t">Quiroz JA, Yatham LN, Palumbo JM, et al. Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder. Biol Psychiatry 2010; 68:156.</a></li><li><a class="nounderline abstract_t">Vieta E, Montgomery S, Sulaiman AH, et al. A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder. Eur Neuropsychopharmacol 2012; 22:825.</a></li><li><a class="nounderline abstract_t">McIntyre RS, Cohen M, Zhao J, et al. Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study. J Affect Disord 2010; 126:358.</a></li><li><a class="nounderline abstract_t">Szegedi A, Durgam S, Mackle M, et al. Randomized, Double-Blind, Placebo-Controlled Trial of Asenapine Maintenance Therapy in Adults With an Acute Manic or Mixed Episode Associated With Bipolar I Disorder. Am J Psychiatry 2018; 175:71.</a></li><li><a class="nounderline abstract_t">Ceron-Litvoc D, Soares BG, Geddes J, et al. Comparison of carbamazepine and lithium in treatment of bipolar disorder: a systematic review of randomized controlled trials. Hum Psychopharmacol 2009; 24:19.</a></li><li><a class="nounderline abstract_t">Calabrese JR, Pikalov A, Streicher C, et al. Lurasidone in combination with lithium or valproate for the maintenance treatment of bipolar I disorder. Eur Neuropsychopharmacol 2017; 27:865.</a></li><li><a class="nounderline abstract_t">Vasudev A, Macritchie K, Watson S, et al. Oxcarbazepine in the maintenance treatment of bipolar disorder. Cochrane Database Syst Rev 2008; :CD005171.</a></li><li><a class="nounderline abstract_t">Pratoomsri W, Yatham LN, Bond DJ, et al. Oxcarbazepine in the treatment of bipolar disorder: a review. Can J Psychiatry 2006; 51:540.</a></li><li><a class="nounderline abstract_t">Popova E, Leighton C, Bernabarre A, et al. Oxcarbazepine in the treatment of bipolar and schizoaffective disorders. Expert Rev Neurother 2007; 7:617.</a></li><li><a class="nounderline abstract_t">Mazza M, Di Nicola M, Martinotti G, et al. Oxcarbazepine in bipolar disorder: a critical review of the literature. Expert Opin Pharmacother 2007; 8:649.</a></li><li><a class="nounderline abstract_t">Berwaerts J, Melkote R, Nuamah I, Lim P. A randomized, placebo- and active-controlled study of paliperidone extended-release as maintenance treatment in patients with bipolar I disorder after an acute manic or mixed episode. J Affect Disord 2012; 138:247.</a></li><li><a class="nounderline abstract_t">Buoli M, Serati M, Altamura AC. Is the combination of a mood stabilizer plus an antipsychotic more effective than mono-therapies in long-term treatment of bipolar disorder? A systematic review. J Affect Disord 2014; 152-154:12.</a></li><li><a class="nounderline abstract_t">Goldberg JF, Brooks JO 3rd, Kurita K, et al. Depressive illness burden associated with complex polypharmacy in patients with bipolar disorder: findings from the STEP-BD. J Clin Psychiatry 2009; 70:155.</a></li><li><a class="nounderline abstract_t">Blanco C, Laje G, Olfson M, et al. Trends in the treatment of bipolar disorder by outpatient psychiatrists. Am J Psychiatry 2002; 159:1005.</a></li><li><a class="nounderline abstract_t">Wolfsperger M, Greil W, Rössler W, Grohmann R. Pharmacological treatment of acute mania in psychiatric in-patients between 1994 and 2004. J Affect Disord 2007; 99:9.</a></li><li><a class="nounderline abstract_t">Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. World J Biol Psychiatry 2009; 10:85.</a></li><li><a class="nounderline abstract_t">Suppes T, Vieta E, Liu S, et al. Maintenance treatment for patients with bipolar I disorder: results from a north american study of quetiapine in combination with lithium or divalproex (trial 127). Am J Psychiatry 2009; 166:476.</a></li><li><a class="nounderline abstract_t">Vieta E, Suppes T, Eggens I, et al. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J Affect Disord 2008; 109:251.</a></li><li><a class="nounderline abstract_t">Macfadden W, Alphs L, Haskins JT, et al. A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently. Bipolar Disord 2009; 11:827.</a></li><li><a class="nounderline abstract_t">Tohen M, Chengappa KN, Suppes T, et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry 2004; 184:337.</a></li><li><a class="nounderline abstract_t">Bowden CL, Vieta E, Ice KS, et al. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial. J Clin Psychiatry 2010; 71:130.</a></li><li><a class="nounderline abstract_t">Preskorn SH, Lacey RL. Polypharmacy: when is it rational? J Psychiatr Pract 2007; 13:97.</a></li><li><a class="nounderline abstract_t">Vieta E, Suppes T, Ekholm B, et al. Long-term efficacy of quetiapine in combination with lithium or divalproex on mixed symptoms in bipolar I disorder. J Affect Disord 2012; 142:36.</a></li><li><a class="nounderline abstract_t">Marcus R, Khan A, Rollin L, et al. Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study. Bipolar Disord 2011; 13:133.</a></li><li><a class="nounderline abstract_t">Woo YS, Bahk WM, Chung MY, et al. Aripiprazole plus divalproex for recently manic or mixed patients with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind maintenance trial. Hum Psychopharmacol 2011; 26:543.</a></li><li><a class="nounderline abstract_t">Suppes T, Webb A, Paul B, et al. Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. Am J Psychiatry 1999; 156:1164.</a></li><li><a class="nounderline abstract_t">Ciapparelli A, Dell'Osso L, Bandettini di Poggio A, et al. Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study. J Clin Psychiatry 2003; 64:451.</a></li><li><a class="nounderline abstract_t">Chang JS, Ha KS, Young Lee K, et al. The effects of long-term clozapine add-on therapy on the rehospitalization rate and the mood polarity patterns in bipolar disorders. J Clin Psychiatry 2006; 67:461.</a></li><li><a class="nounderline abstract_t">Yatham LN, Beaulieu S, Schaffer A, et al. Optimal duration of risperidone or olanzapine adjunctive therapy to mood stabilizer following remission of a manic episode: A CANMAT randomized double-blind trial. Mol Psychiatry 2016; 21:1050.</a></li><li><a class="nounderline abstract_t">Denicoff KD, Smith-Jackson EE, Bryan AL, et al. Valproate prophylaxis in a prospective clinical trial of refractory bipolar disorder. Am J Psychiatry 1997; 154:1456.</a></li><li><a class="nounderline abstract_t">Bocchetta A, Chillotti C, Severino G, et al. Carbamazepine augmentation in lithium-refractory bipolar patients: a prospective study on long-term prophlyactic effectiveness. J Clin Psychopharmacol 1997; 17:92.</a></li><li><a class="nounderline abstract_t">Baethge C, Baldessarini RJ, Mathiske-Schmidt K, et al. Long-term combination therapy versus monotherapy with lithium and carbamazepine in 46 bipolar I patients. J Clin Psychiatry 2005; 66:174.</a></li><li><a class="nounderline abstract_t">BALANCE investigators and collaborators, Geddes JR, Goodwin GM, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet 2010; 375:385.</a></li><li><a class="nounderline abstract_t">Denicoff KD, Smith-Jackson EE, Disney ER, et al. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry 1997; 58:470.</a></li><li><a class="nounderline abstract_t">van der Loos ML, Mulder P, Hartong EG, et al. Long-term outcome of bipolar depressed patients receiving lamotrigine as add-on to lithium with the possibility of the addition of paroxetine in nonresponders: a randomized, placebo-controlled trial with a novel design. Bipolar Disord 2011; 13:111.</a></li><li><a class="nounderline abstract_t">Vieta E, Cruz N, García-Campayo J, et al. A double-blind, randomized, placebo-controlled prophylaxis trial of oxcarbazepine as adjunctive treatment to lithium in the long-term treatment of bipolar I and II disorder. Int J Neuropsychopharmacol 2008; 11:445.</a></li><li><a class="nounderline abstract_t">Carlson BX, Ketter TA, Sun W, et al. Aripiprazole in combination with lamotrigine for the long-term treatment of patients with bipolar I disorder (manic or mixed): a randomized, multicenter, double-blind study (CN138-392). Bipolar Disord 2012; 14:41.</a></li><li><a class="nounderline abstract_t">Perlis RH, Ostacher MJ, Miklowitz DJ, et al. Benzodiazepine use and risk of recurrence in bipolar disorder: a STEP-BD report. J Clin Psychiatry 2010; 71:194.</a></li><li class="breakAll">Handbook of Psychiatric Measures, Second Edition, Rush Jr AJ, First MB, Blacker D (Eds), American Psychiatric Publishing, Inc, Washington, DC.</li><li><a class="nounderline abstract_t">Born C, Amann BL, Grunze H, et al. Saving time and money: a validation of the self ratings on the prospective NIMH Life-Chart Method (NIMH-LCM). BMC Psychiatry 2014; 14:130.</a></li><li><a class="nounderline abstract_t">Denicoff KD, Smith-Jackson EE, Disney ER, et al. Preliminary evidence of the reliability and validity of the prospective life-chart methodology (LCM-p). J Psychiatr Res 1997; 31:593.</a></li><li><a class="nounderline abstract_t">Denicoff KD, Leverich GS, Nolen WA, et al. Validation of the prospective NIMH-Life-Chart Method (NIMH-LCM-p) for longitudinal assessment of bipolar illness. Psychol Med 2000; 30:1391.</a></li><li><a class="nounderline abstract_t">Ketter TA. Strategies for monitoring outcomes in patients with bipolar disorder. Prim Care Companion J Clin Psychiatry 2010; 12:10.</a></li><li><a class="nounderline abstract_t">Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001; 16:606.</a></li><li><a class="nounderline abstract_t">Bauer MS, Crits-Christoph P, Ball WA, et al. Independent assessment of manic and depressive symptoms by self-rating. Scale characteristics and implications for the study of mania. Arch Gen Psychiatry 1991; 48:807.</a></li><li><a class="nounderline abstract_t">Gaynes BN, DeVeaugh-Geiss J, Weir S, et al. Feasibility and diagnostic validity of the M-3 checklist: a brief, self-rated screen for depressive, bipolar, anxiety, and post-traumatic stress disorders in primary care. Ann Fam Med 2010; 8:160.</a></li><li><a class="nounderline abstract_t">Malhi GS, McAulay C, Das P, Fritz K. Maintaining mood stability in bipolar disorder: a clinical perspective on pharmacotherapy. Evid Based Ment Health 2015; 18:1.</a></li><li><a class="nounderline abstract_t">Suppes T, Baldessarini RJ, Faedda GL, Tohen M. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry 1991; 48:1082.</a></li><li><a class="nounderline abstract_t">Yazici O, Kora K, Polat A, Saylan M. Controlled lithium discontinuation in bipolar patients with good response to long-term lithium prophylaxis. J Affect Disord 2004; 80:269.</a></li><li><a class="nounderline abstract_t">Baldessarini RJ, Tondo L, Floris G, Rudas N. Reduced morbidity after gradual discontinuation of lithium treatment for bipolar I and II disorders: a replication study. Am J Psychiatry 1997; 154:551.</a></li><li><a class="nounderline abstract_t">Faedda GL, Tondo L, Baldessarini RJ, et al. Outcome after rapid vs gradual discontinuation of lithium treatment in bipolar disorders. Arch Gen Psychiatry 1993; 50:448.</a></li><li><a class="nounderline abstract_t">Kishi T, Sakuma K, Okuya M, et al. Effects of a conventional mood stabilizer alone or in combination with second-generation antipsychotics on recurrence rate and discontinuation rate in bipolar I disorder in the maintenance phase: A systematic review and meta-analysis of randomized, placebo-controlled trials. Bipolar Disord 2021; 23:789.</a></li><li><a class="nounderline abstract_t">Scott J, Colom F, Vieta E. A meta-analysis of relapse rates with adjunctive psychological therapies compared to usual psychiatric treatment for bipolar disorders. Int J Neuropsychopharmacol 2007; 10:123.</a></li><li><a class="nounderline abstract_t">Malhi GS, Adams D, Lampe L, et al. Clinical practice recommendations for bipolar disorder. Acta Psychiatr Scand Suppl 2009; :27.</a></li><li><a class="nounderline abstract_t">Frank E, Swartz HA, Mallinger AG, et al. Adjunctive psychotherapy for bipolar disorder: effects of changing treatment modality. J Abnorm Psychol 1999; 108:579.</a></li><li><a class="nounderline abstract_t">Zisselman MH, Rosenquist PB, Curlik SM. Long-term weekly continuation electroconvulsive therapy: a case series. J ECT 2007; 23:274.</a></li><li><a class="nounderline abstract_t">Yero SA, McKinney T, Petrides G, et al. Successful use of electroconvulsive therapy in 2 cases of persistent sexual arousal syndrome and bipolar disorder. J ECT 2006; 22:274.</a></li><li><a class="nounderline abstract_t">Sienaert P, Peuskens J. Electroconvulsive therapy: an effective therapy of medication-resistant bipolar disorder. Bipolar Disord 2006; 8:304.</a></li><li><a class="nounderline abstract_t">Nascimento AL, Appolinario JC, Segenreich D, et al. Maintenance electroconvulsive therapy for recurrent refractory mania. Bipolar Disord 2006; 8:301.</a></li><li><a class="nounderline abstract_t">Tsao CI, Jain S, Gibson RH, et al. Maintenance ECT for recurrent medication-refractory mania. J ECT 2004; 20:118.</a></li><li><a class="nounderline abstract_t">Vaidya NA, Mahableshwarkar AR, Shahid R. Continuation and maintenance ECT in treatment-resistant bipolar disorder. J ECT 2003; 19:10.</a></li><li><a class="nounderline abstract_t">Russell JC, Rasmussen KG, O'Connor MK, et al. Long-term maintenance ECT: a retrospective review of efficacy and cognitive outcome. J ECT 2003; 19:4.</a></li><li><a class="nounderline abstract_t">Vanelle JM, Loo H, Galinowski A, et al. Maintenance ECT in intractable manic-depressive disorders. Convuls Ther 1994; 10:195.</a></li><li><a class="nounderline abstract_t">Bonds C, Frye MA, Coudreaut MF, et al. Cost reduction with maintenance ECT in refractory bipolar disorder. J ECT 1998; 14:36.</a></li><li><a class="nounderline abstract_t">Madero S, Anmella G, Sagué-Vilavella M, et al. Evaluating maintenance electroconvulsive therapy in Bipolar Disorders: 3-year mirror-image study. J Affect Disord 2022; 298:58.</a></li><li><a class="nounderline abstract_t">Michalak EE, Suto MJ, Barnes SJ, et al. Effective self-management strategies for bipolar disorder: A community-engaged Delphi Consensus Consultation study. J Affect Disord 2016; 206:77.</a></li><li><a class="nounderline abstract_t">Goulding EH, Dopke CA, Rossom R, et al. Effects of a Smartphone-Based Self-management Intervention for Individuals With Bipolar Disorder on Relapse, Symptom Burden, and Quality of Life: A Randomized Clinical Trial. JAMA Psychiatry 2023; 80:109.</a></li></ol></div><div id="topicVersionRevision">Topic 680 Version 67.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, Arlington, VA 2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16449474" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25845021" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Recovery and recurrence following a first episode of mania: a systematic review and meta-analysis of prospectively characterized cohorts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22510036" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Maintenance therapies in bipolar disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12755652" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Factors associated with suicide attempts in 648 patients with bipolar disorder in the Stanley Foundation Bipolar Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11765094" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Identifying and managing suicide risk in bipolar patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12091194" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Suicide attempts in patients with bipolar I disorder during acute and maintenance phases of intensive treatment with pharmacotherapy and adjunctive psychotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15323586" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Bipolar patients with suicidal behavior: toward the identification of a clinical subgroup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15119913" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Suicide attempts and ideation in patients with bipolar I disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15285972" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Correlates of 1-year prospective outcome in bipolar disorder: results from the Stanley Foundation Bipolar Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Neurocognitive deficits in bipolar disorder</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20390474" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Mechanisms of illness progression in the recurrent affective disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20923622" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Complexity of pharmacologic treatment required for sustained improvement in outpatients with bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25012681" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Starting lithium prophylaxis early v. late in bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25004200" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Cognitive change in the year after a first manic episode: association between clinical outcome and cognitive performance early in the course of bipolar I disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27759214" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Neuroprogression and episode recurrence in bipolar I disorder: A study of gray matter volume changes in first-episode mania and association with clinical outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23237061" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23480132" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23480132" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26979387" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12622659" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21383262" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21292927" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Unrecognised bipolar disorder in primary care patients with depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12063145" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Mortality of patients with mood disorders: follow-up over 34-38 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24816046" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Antipsychotics, mood stabilisers, and risk of violent crime.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19791827" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The management of individuals with bipolar disorder: a review of the evidence and its integration into clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17888516" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Relationship of open acute mania treatment to blinded maintenance outcome in bipolar I disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22054050" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23361837" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26580001" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Florida Best Practice Psychotherapeutic Medication Guidelines for Adults With Bipolar Disorder: A Novel, Practical, Patient-Centered Guide for Clinicians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28437764" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The use of lithium for the treatment of bipolar disorder: Recommendations from clinical practice guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29536616" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33353391" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33353391" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33353391" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27160812" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Reproductive and metabolic abnormalities in women taking valproate for bipolar disorder: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17547586" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: a systematic review of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28254958" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Quetiapine v. lithium in the maintenance phase following a first episode of mania: randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17042835" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27167638" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Self-harm, Unintentional Injury, and Suicide in Bipolar Disorder During Maintenance Mood Stabilizer Treatment: A UK Population-Based Electronic Health Records Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24132760" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22404704" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : A randomised, placebo-controlled 52-week trial of continued quetiapine treatment in recently depressed patients with bipolar I and bipolar II disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20712749" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Lamotrigine versus lithium as maintenance treatment in bipolar I disorder: an open, randomized effectiveness study mimicking clinical practice. The 6th trial of the Danish University Antidepressant Group (DUAG-6).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17960961" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20859108" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Strategies for addressing adherence problems in patients with serious and persistent mental illness: recommendations from the expert consensus guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28146613" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Efficacy and Safety of Aripiprazole Once-Monthly in the Maintenance Treatment of Bipolar I Disorder: A Double-Blind, Placebo-Controlled, 52-Week Randomized Withdrawal Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19160237" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Olanzapine in long-term treatment for bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19828571" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Olanzapine in the long-term treatment of bipolar disorder: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15337666" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21346617" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Metabolic effects of olanzapine in patients with newly diagnosed psychosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20838345" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Cardiovascular aspects of antipsychotics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16449478" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20227682" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22503488" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20537396" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28946761" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Randomized, Double-Blind, Placebo-Controlled Trial of Asenapine Maintenance Therapy in Adults With an Acute Manic or Mixed Episode Associated With Bipolar I Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19053079" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Comparison of carbamazepine and lithium in treatment of bipolar disorder: a systematic review of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28689688" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Lurasidone in combination with lithium or valproate for the maintenance treatment of bipolar I disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18254071" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Oxcarbazepine in the maintenance treatment of bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16933591" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Oxcarbazepine in the treatment of bipolar disorder: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17563245" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Oxcarbazepine in the treatment of bipolar and schizoaffective disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17376019" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Oxcarbazepine in bipolar disorder: a critical review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22377512" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : A randomized, placebo- and active-controlled study of paliperidone extended-release as maintenance treatment in patients with bipolar I disorder after an acute manic or mixed episode.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24041717" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Is the combination of a mood stabilizer plus an antipsychotic more effective than mono-therapies in long-term treatment of bipolar disorder? A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19210946" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Depressive illness burden associated with complex polypharmacy in patients with bipolar disorder: findings from the STEP-BD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12042190" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Trends in the treatment of bipolar disorder by outpatient psychiatrists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16989907" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Pharmacological treatment of acute mania in psychiatric in-patients between 1994 and 2004.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19347775" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19289454" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Maintenance treatment for patients with bipolar I disorder: results from a north american study of quetiapine in combination with lithium or divalproex (trial 127).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18579216" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19922552" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15056579" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20122373" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17414685" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Polypharmacy: when is it rational?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23062763" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Long-term efficacy of quetiapine in combination with lithium or divalproex on mixed symptoms in bipolar I disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21443567" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22134973" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Aripiprazole plus divalproex for recently manic or mixed patients with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind maintenance trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10450255" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12716249" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16649834" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : The effects of long-term clozapine add-on therapy on the rehospitalization rate and the mood polarity patterns in bipolar disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26460229" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Optimal duration of risperidone or olanzapine adjunctive therapy to mood stabilizer following remission of a manic episode: A CANMAT randomized double-blind trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9326833" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Valproate prophylaxis in a prospective clinical trial of refractory bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10950470" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Carbamazepine augmentation in lithium-refractory bipolar patients: a prospective study on long-term prophlyactic effectiveness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15705002" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Long-term combination therapy versus monotherapy with lithium and carbamazepine in 46 bipolar I patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20092882" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9413412" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21320258" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Long-term outcome of bipolar depressed patients receiving lamotrigine as add-on to lithium with the possibility of the addition of paroxetine in nonresponders: a randomized, placebo-controlled trial with a novel design.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18346292" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : A double-blind, randomized, placebo-controlled prophylaxis trial of oxcarbazepine as adjunctive treatment to lithium in the long-term treatment of bipolar I and II disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22329471" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Aripiprazole in combination with lamotrigine for the long-term treatment of patients with bipolar I disorder (manic or mixed): a randomized, multicenter, double-blind study (CN138-392).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20193647" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Benzodiazepine use and risk of recurrence in bipolar disorder: a STEP-BD report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20193647" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Benzodiazepine use and risk of recurrence in bipolar disorder: a STEP-BD report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24886463" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Saving time and money: a validation of the self ratings on the prospective NIMH Life-Chart Method (NIMH-LCM).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9368200" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Preliminary evidence of the reliability and validity of the prospective life-chart methodology (LCM-p).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11097079" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Validation of the prospective NIMH-Life-Chart Method (NIMH-LCM-p) for longitudinal assessment of bipolar illness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20628501" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Strategies for monitoring outcomes in patients with bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11556941" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : The PHQ-9: validity of a brief depression severity measure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1929771" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Independent assessment of manic and depressive symptoms by self-rating. Scale characteristics and implications for the study of mania.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20212303" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Feasibility and diagnostic validity of the M-3 checklist: a brief, self-rated screen for depressive, bipolar, anxiety, and post-traumatic stress disorders in primary care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25165167" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Maintaining mood stability in bipolar disorder: a clinical perspective on pharmacotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1845226" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Risk of recurrence following discontinuation of lithium treatment in bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15207941" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Controlled lithium discontinuation in bipolar patients with good response to long-term lithium prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9090345" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Reduced morbidity after gradual discontinuation of lithium treatment for bipolar I and II disorders: a replication study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8498879" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Outcome after rapid vs gradual discontinuation of lithium treatment in bipolar disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33561884" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Effects of a conventional mood stabilizer alone or in combination with second-generation antipsychotics on recurrence rate and discontinuation rate in bipolar I disorder in the maintenance phase: A systematic review and meta-analysis of randomized, placebo-controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16787554" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : A meta-analysis of relapse rates with adjunctive psychological therapies compared to usual psychiatric treatment for bipolar disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19356155" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Clinical practice recommendations for bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10609422" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Adjunctive psychotherapy for bipolar disorder: effects of changing treatment modality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18090702" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Long-term weekly continuation electroconvulsive therapy: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17143162" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Successful use of electroconvulsive therapy in 2 cases of persistent sexual arousal syndrome and bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16696836" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Electroconvulsive therapy: an effective therapy of medication-resistant bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16696835" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Maintenance electroconvulsive therapy for recurrent refractory mania.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15167429" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Maintenance ECT for recurrent medication-refractory mania.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12621271" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Continuation and maintenance ECT in treatment-resistant bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12621270" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Long-term maintenance ECT: a retrospective review of efficacy and cognitive outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7834256" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Maintenance ECT in intractable manic-depressive disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9661092" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Cost reduction with maintenance ECT in refractory bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34715196" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Evaluating maintenance electroconvulsive therapy in Bipolar Disorders: 3-year mirror-image study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27466745" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Effective self-management strategies for bipolar disorder: A community-engaged Delphi Consensus Consultation study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36542401" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Effects of a Smartphone-Based Self-management Intervention for Individuals With Bipolar Disorder on Relapse, Symptom Burden, and Quality of Life: A Randomized Clinical Trial.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
